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ABSTRACT 
 
 
Cellulose Acetate (CA) is a polymer extensively used in pharmaceutical 
applications. Because of the hydrophobic nature and good film properties of CA, it is a 
good polymer candidate for sustained release matrix tablets. Sustained release matrix 
tablets of cellulose acetate can be prepared by direct compression or wet granulation 
methods. However, previous studies showed that a large amount of CA was required to 
achieve the desired sustained release profile for a sparingly soluble drug and it was 
difficult to formulate a highly water soluble drug by using CA as the retarding agent. 
Some studies concluded that CA is very sensitive to the solubility of the drug and it is not 
suitable for retarding the release for highly water soluble drugs. 
 
There are two aims in our study. One is to modify the physical characteristic of 
the CA by using a co-processing technique and increase the capacity of cellulose acetate 
to control the drug release rate. The other is to modulate the drug release rate from the 
hydrophobic sustained release tablets and apply these formulation strategies to reduce the 
burst release and enhance the final release. 
 
Three different process methods including heat treatment, wet granulation and 
spray drying were used to prepare the co-processed excipients with CA, plasticizer and 
inert excipient. The physical, flow and compaction properties of the co-processed 
excipients were evaluated.  All the co-processed excipients prepared in this study all 
showed good flow characteristic. The spray dried process produced high porous particles 
with large surface area. These particles required the least energy for plastic deformation 
during compression and formed the tablets with highest mechanical strength. The wet 
granulated excipients showed moderate plastic deformation capacity and resulting tablets 
with acceptable tensile strength. The heat treated excipients required more energy to 
deform under compression pressure than the other two methods and the resulting tablets 
have poor mechanical properties. For all preparation methods, addition of 10% plasticizer 
increases the plasticity of the final excipient and decreases the tablet tensile strength.  The 
tablets containing hydrophilic plasticizer showed better tensile strength than the 
hydrophobic plasticizer. The tensile strength of the tablets increased at low plasticizer 
concentration and the reverse effect was observed on higher plasticizer concentration. 
Both wet granulated and spray dried excipients showed desired flowability and 
acceptable compactability which makes them good excipient candidates for direct 
compression formulation.  
 
The sustained release characteristic of the co-processed excipients were evaluated 
by a freely water soluble drug propranolol hydrochloride. The spray dried co-processed 
excipients demonstrated slower drug release profile than the excipients prepared by the 
other two processing methods. The surface morphology and initial water penetration 
study found the spray dried co-processed excipient can form a continuous film like 
structure on the tablet surface which can effectively prevent water penetration and drug 
diffusion. The drug release rate from the matrix tablets containing the novel spray dried 
excipients can be decreased by increasing the hydrophobicity of the plasticizer and 
 vi 
plasticizer concentration. The drug release rate from the matrix was affected by the 
compression force but not the pH of the dissolution medium. Based on porosity results 
and drug release mechanism study, addition of plasticizer to the co-processed excipients 
showed a decrease in the drug release rate due to three reasons: a) decrease in the 
porosity of the tablet; b) decrease in the effective diffusion coefficient; c) assist in 
maintaining tablet structure during dissolution. 
 
Three different types of pore formers were tried to modulate drug release 
characteristics from the plastic inert matrix. With the help of pore formers lactose and 
Starch1500®, both observed improved final release as well as increased burst release. 
When a small amount of hydrophilic polymer pore former was incorporated into the 
formulation, it showed a limited burst release initially and complete release at final stage. 
The optical microscopy results revealed the initial gel formation on the tablet surface 
with development of a swollen porous structure in the matrix network during dissolution. 
The drug release rate from this swellable porous matrix system is independent with the 
type and the particle size of hydrophilic polymer and the pH of dissolution medium. The 
drug release rate increased when the hydrophilic polymer concentration was less than 
5%. Further increase of the hydrophilic polymer concentration to 10% did not further 
increase the drug release rate. The low viscosity grade hydrophilic polymer resulted in 
rapid burst release and incomplete final release, while middle to high viscosity grades of 
hydrophilic polymer avoided these problems. The drug release is controlled by both drug 
diffusion and polymer relaxation. The Fickian diffusion is the dominant release 
mechanism at the initial stage and the polymer relaxation becomes dominant thereafter. 
 
The spray dried co-processed excipient and the swollen porous matrix system 
were used to develop the sustained release matrix formulation for three different drugs 
with different solubility. The optimized formulations for these three drugs either meet the 
USP specifications or have similar dissolution profile to the commercial product. For a 
freely water soluble drug propranolol hydrochloride, a roller compaction method was 
applied to reduce the initial burst release. The tablets prepared by the roller compacted 
granules showed suppressed burst release and complete final release. For the sparingly 
water soluble drug theophylline, incorporating 10% hydrophilic polymer can successfully 
reduce the burst release as well as improve the final release. Two successful sustained 
release formulations of the poorly water soluble drug glipizide were obtained by using 
the plasticized co-processed excipient. Both of them have similar dissolution profile as 
the commercial product Gluctrol XL®. But the formulation prepared with lactose as pore 
former showed a large variation in dissolution profile while another formulation prepared 
with both lactose and hydrophilic polymer as pore formers exhibited less variation in 
dissolution profile and a higher f2 value. 
 
In conclusion, the spray dried co-processed plasticized cellulose acetate 
developed in this study exhibits good physical and mechanical properties. It can be used 
alone or combined with hydrophilic polymers to control the release rate of the drugs with 
different solubility. 
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 1 
Chapter 1. Introduction 
 
 
Oral drug delivery is the most preferred route for delivering drugs to the body. 
The popularity is due to the distinct advantages such as convenient to use, high patient 
compliance, easy manufacture and relatively low cost. Traditional oral drug delivery 
systems including oral suspensions, oral solutions, immediate release tablets and capsules 
often cannot maintain the constant drug concentration in the blood, therefore frequent 
doses were required for the drugs with a short half-life. In addition side effects may also 
occur for the drugs with a narrow therapeutic window. Oral sustained release systems 
have been developed since 1950 for solving these problems. These systems are designed 
to control the drug release rate from gastrointestinal tract to extend the duration of action 
and minimize the fluctuation of drug concentration and achieve better therapeutic 
performance. In addition to the clinical advantages, the sustained release system can also 
help to extend the product life-cycle. That becomes an important strategy for 
management of product life-cycle for pharmaceutical industry. 
 
The first sustained release product was developed in 1950 using the trade name 
Spansules® [1]. It was a capsule form which contained a large number of beads. The 
sustained release profile was achieved by coating a hydrophobic wax on beads containing 
a sugar core and drug layer. Over the last six decades, a great number of sustained release 
products were commercialized and a number of new sophisticated technologies were 
developed and introduced to this area. The major commercialized sustained release 
systems can be summarized as: matrix system, reservoir system and osmotic system. 
Drug release is generally controlled by one or a combination of the following 
mechanisms: drug diffusion, system swelling, system erosion or osmotic pressure.  
 
Among all the sustained release systems, the matrix system is the simplest and the 
most widely used sustained release system. This is due to the cost effective manufacture 
process and the accommodation for a wide range of drugs with different chemical and 
physical properties. The majority of the commercialized matrix systems are in the form of 
tablets.  The preparation process and equipment for preparation of matrix tablets is 
usually similar to the conventional tablets. 
 
 
1.1 Oral Matrix Sustained Release Tablet 
 
In a matrix tablet, the drug is uniformly blended with other excipients including 
rate-controlling material(s) and other inactive ingredients. Drug release is controlled 
either by drug diffusion and/or matrix erosion. Based on the properties of rate-controlling 
material, the matrix system can be divided into two types: hydrophilic matrix and 
hydrophobic matrix. 
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1.1.1 Hydrophilic matrix tablet 
 
In a hydrophilic matrix tablet, the rate-controlling material is the hydrophilic 
polymer. Upon contact with the aqueous medium or gastrointestinal fluid, the water 
penetrates into the free spaces between the chains of hydrophilic polymer. The rigid 
polymer relaxes and become flexible. A glassy to rubbery phase transformation of the 
hydrophilic polymer occurs. As a result, the tablet swells and a viscous gel layer is 
formed on the surface of tablet. The tablet consists of two different states: the glassy core 
and rubbery gel layer. The lengthened and torturous diffusion pathway of the viscous gel 
layer can hinder the release of embedded drug. As more water enters the tablet, the 
concentration of the hydrophilic polymer at the surface dilutes and the disentanglement 
concentration can be reached. The concentration at which polymeric chains are 
disentangled is related to the rheological properties of the gels and corresponds to the 
tablet erosion. The tablet can be completely eroded when water continues to penetrate 
towards the core of the tablet through the gel layer. During dissolution, three driving 
forces are present in the polymer network:  the penetrating concentration gradient, 
polymer concentration gradient and osmotic force. Drug release from the hydrophilic 
matrices is controlled by diffusion and/or polymer erosion. 
 
There are three broad categories of polymers that commonly used in the 
preparation of hydrophilic matrices. 
 
 a) Cellulose derivatives: methylcellulose (MC); hydroxyethylcellulose 
(HEC); hydroxypropylcellulose (HPC); hydroxypropylmethylcellulose 
(HPMC); and sodium carboxymethylcellulose (NaCMC).  
 b) Natural polymers: sodium alginate; xanthan gum; carrageenan; locust bean 
gum; chitosan; guar gum; pectin and modified starches.  
 c) Synthetic polymers: polyacrylic acid derivative (carbopol); polyethylene 
oxide (PEO), polyvinyl pyrrolidone (PVP). 
 
These polymers also can be divided into ionic and non-ionic. Non-ionic polymers 
such as HPMC and PEO will not be ionized in the water and their hydration and erosion 
are independent of pH. On the contrary, the ionic polymers such as chitosan and 
Carbopol exhibit pH dependent hydrophilicity due to ionization of the polymer chain 
under a certain pH.  
 
Of all the polymers, HPMC is one of the most widely used polymers in 
hydrophilic matrices. It is cellulose ether containing methoxyl and hydroxypropyl groups. 
Different substitutions and viscosity grades of HPMC are commercially available. The 
key features and advantages of HPMC included [2]:  
 
 a) Non-ionic polymer resulting in pH independent drug release performance. 
 b) Stable within a wide pH range and resistant to enzymatic degradation.  
 c) Less chance for chemical interaction or complexation with other 
formulation components. 
 d) Accommodation of various drugs and a high level of drug loading. 
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 e) Good compaction characteristics in both direct compression and 
granulation.  
 f) Easy to manufacture. 
 
Another widely used hydrophilic polymer is carbopol. It is a synthetic high 
molecular weight ionic polymer prepared by crosslinking acrylic acid with allyl sucrose 
or allylpentaerythritol. Carbopol is also available with different viscosity and particle size 
grades such as 934P, 974P, 971P and 71G [3]. They are not soluble, but swellable in 
water. Owing to the present of carboxyl group in the polymer chain, the swellability of 
carbopol polymers is pH dependent and the maximum swellability is 1,000 times their 
original volume at pH6.0 [4]. Unlike the traditional linear polymer like HPMC and HPC 
which form continuous gel layer by the single entangled polymer chains, the crosslinked 
carbopol polymer will form a discrete microgel made of many polymer particles. The 
drug can be entrapped into this microgel and slowly release by diffusion. Since carbopol 
doesn’t dissolve in the water, the erosion doesn’t take place in this system. When the 
system is fully hydrated, the osmotic pressure generated inside the gel network will break 
the structure of hydrogel by shedding off the discrete pieces. With this unique feature, 
relatively small amount of the carbopol is required to formulate the hydrophilic matrix 
tablet. 
 
The factors involved in controlling drug release from hydrophilic matrix tablets 
were extensively investigated. Drug release from the hydrophilic matrix tablets  was less 
affected by the  process  variables such as compaction pressure, mixing time and 
granulation methods [5, 6]. On the other hand, the formulation variables including drug 
properties, polymer properties, filler choice and geometric dimension of the matrix were 
crucial to the drug release from the matrix tablets. 
 
The drug release behavioral from the hydrophilic matrix tablet  is a function of 
drug solubility which was analyzed by the model-independent and model-dependent 
methods [7]. The study revealed the primary rate limiting factor is matrix erosion for the 
drugs with poor solubility. When the solubility of the drug is between 0.5mg/ml to 
5mg/ml, the drug release rate was controlled by both matrix erosion and medium 
infiltration into the matrix. In the case of drug solubility more than 5 mg/ml, the rate 
limiting factor was only the infiltration of medium to the matrix but not the drug 
solubility. In general, the primary release mechanism of water soluble drug is diffusion 
and the erosion is the major release mechanism for water insoluble drug. The drugs with 
high water solubility always exhibit fast release and the rapid initial release so called 
burst release due to the rapid surface drug diffusion. It is a challenge for formulating the 
highly water soluble drugs with high dose using the hydrophilic matrix tablet.  
 
In order to obtain a complete gel formation and prolonged drug release, certain 
polymer concentration should be used in the matrix tablet. Utilizing HPMC as an 
example, 20%-50% is the typical usage level. For some of the water soluble drugs, when 
the polymer concentration reaches to a particular level, future increase of the polymer 
level would not sequentially suppress the drug release [8, 9]. The polymers with high 
viscosity grades typically have a fast hydration rate and are more resistant to dilution and 
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erosion. This result a strong and thicken gel layer and slower drug dissolution. The high 
viscosity polymers are generally recommended for highly water soluble drug since the 
strong and tortuous gel layer provides more resistance to drug diffusion. The particle size 
of the hydrophilic polymer also can affect the drug release from the matrix tablet. The 
hydrophilic polymers with smaller particle size have a rapid hydration rate and quick gel 
formation, therefore better controlled release properties [2, 10] Some polymer 
manufactures such as Dow chemical provide specific fine particle grades for controlled 
release applications. It was reported the hydrophobicity of the polymer also plays a role 
on the drug release.  
 
Incorporation of filler to matrix tablet can improve the flow properties of the 
granules and mechanical strength of the tablets. It modifies not only the physical 
properties, but the filler can also manipulate the drug release from the matrix. It is a 
common strategy for formulation development of the hydrophilic matrix tablet. Water 
soluble fillers like polyethylene glycol, lactose can increase drug release, because the 
water penetration was enhanced and the tortuosity of the gel matrix was decreased after 
the water soluble filler leached out from the system [5]. The insoluble fillers like 
dicalcium phosphate and microcrystalline cellulose exhibit a relatively slower release 
rate. The water swellable filler partially pregelatinized maize starch (Starch 1500) was 
found to have synergistic interaction with the polymer and prevented the water absorption  
into the matrix, thus slowing down the drug release [7, 11]. 
 
Geometric factors, including the shape and size of the tablet were reported to 
affect the drug release from the matrix tablet. The surface area to volume ratio (S/V) was 
found to be one of the key variables. The tablets with large S/V exhibit fast drug release 
rate since more surface is available for drug diffusion. The similar release profile can be 
obtained from the tablets with same S/V, regardless the tablet shape and dose [12, 13]. 
For hydrophilic matrix tablet, the geometry of the tablet keeps changing and the S/V is 
not constant during dissolution. This results in the variation of the drug release rate at 
different time points. Modification of the geometry of the tablets to maintain the constant 
S/V during dissolution was approved to be effective to achieve the constant release rate. 
This modification includes the Geomatrix® technology (multi-layer tablet), Smartrix® 
technology (triple-layered tablet with specific shape in core layer), Dome Matrix® 
technology (tablet structure arranged by different elementary modules), cup-in-core 
device and Donald shape tablets. However, many of these designs are very complicated 
and difficult to manufacture [14]. 
 
The combination of a hydrophilic polymer with another hydrophilic or 
hydrophobic polymer to achieve better drug release performance was extensively 
investigated. The decreased burst release was observed when a hydrophobic polymer was 
incorporated into the hydrophilic matrix. This was explained by the increase in the 
hydrophobicity of the tablet surface and the decrease of water penetration into matrix [15, 
16]. However, when a higher ratio of hydrophobic polymer was present in the matrix, it 
disrupted gel strength and faster drug dissolution occurred [17-19]. The interaction 
between the nonionic polymer HPMC and anionic polymer NaCMC helps to overcome 
the burst effect and lag time associated with the individual polymers. A linear release 
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profile can be achieved by use of this combination [20, 21]. Combination of the nonionic 
polymer with the anionic polymer was also utilized to obtain a pH independent profile for 
basic drugs. The strong interaction of the basic drug and the anionic polymer leads to the 
formation of an insoluble drug-polymer complex. This complex retarded the drug release 
from the matrix and minimized the pH effect [22, 23]. The similar phenomenon was 
appeared while using the combination of nonionic polymer with a cationic polymer and 
an anionic polymer with a cationic polymer [24-26]. 
 
In general, development of the hydrophilic matrix tablets is the state of the art 
technique. Many formulation factors involved in the development need to be taken into 
consideration in order to obtain the desired drug release profile and ideal in-vivo 
performance. 
 
 
1.1.2 Hydrophobic matrix tablet 
 
The primary rate limiting components in a hydrophobic matrix tablet are water 
insoluble polymers, waxes or combination of both. The examples of hydrophobic waxes 
material include glycerides, fatty acids and alcohols, hydrogenated vegetable oils [17, 27, 
28]. The commonly used hydrophobic polymers consist of ethyl cellulose (EC), cellulose 
acetate (CA), methacrylic acid copolymers (Eudragit®), starch acetates and poly vinyl 
acetate (PVA) [29-34]. 
 
In hydrophobic matrix tablets, the drug is mixed with the hydrophobic 
components and other excipients, and then be compressed into a tablet. Sustained release 
profile was achieved by the drug diffusion through the water filled capillary channels or 
pores existing in tablet network. The drug release behaviors directly related to the 
porosity and pore structure from the matrix [35]. Such type of matrix is inert in the 
presence of water and gastrointestinal fluid, and maintains its size and dimensions during 
drug dissolution. The liquid penetration through the matrix network is the rate-controlling 
step. The typical mechanism of drug release is diffusion. The drug release from the 
hydrophobic matrix tablet is a proportional to the square root of time and can be 
described by the Higuchi equation [36]. 
 
The formulation factors and process factors which affect the drug release from the 
hydrophobic matrix tablets were also investigated by many scientists. The drug 
properties, particle size of the polymers, formulation variables and process variables were 
critical factors of drug release from the hydrophobic matrix tablets. 
 
Neau et al [37] studied the drug solubility effect on drug release mechanism from 
ethylcellulose matrix tablets. Increased drug release rate with an increase of drug 
solubility was observed for formulations with different drug loadings. At low drug 
loading, the contribution of polymer relaxation to the drug release diminishes with 
decreasing drug solubility. Drug solubility effect on drug release was also found in 
cellulose acetate matrix tablet [38]. The sustained release profile was only obtained for 
the sparingly water soluble drug theophylline, but not for highly soluble drug dyphylline 
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and proxyphylline when cellulose acetate was used as the retarding agent. Additional 
barrier-coating was required for the highly soluble drug formulations to prevent the 
massive release and matrix erosion. 
 
The particle size of the polymer is a very important factor in controlling the drug 
release from the hydrophobic matrix tablet. The coarse grade of hydrophobic polymers 
failed  to achieve the sustained drug release profile while the same viscosity grade of fine 
particles can effectively control the drug release [39]. According to the percolation 
theory, fewer drug clusters can be formed when more polymer particles surrounded the 
drug. Since more polymer particles were presented in the fine particle grades, slower 
drug release can be obtained [40]. 
 
Dabbagh et al [41] investigated the effect of polymer concentration, compression 
pressure and hydrophilic polymers on drug release from hydrophobic ethylcellulose 
matrix tablets. The results demonstrated the influence of polymer concentration on drug 
release rate. Decreased drug release rate was observed as the polymer concentration 
increased in the matrix, however the polymer concentration did not alter the drug release 
mechanism. The drug release rate was also affected by the compression pressure. The 
drug release rate was decreased as the compression pressure was increased to 39.4 MNm-
2 initially. But as the compression pressure reached to the range of 78.7-393.7 MNm-2, the 
drug release was relatively unaffected owing to the elasticity of the ethylcellulose. Drug 
release rate was increased by incorporation of hydrophilic polymer NaCMC or HPMC 
K4M to the hydrophobic matrix. Rapid water uptake and discontinuous gel formation 
were responsible for the fast drug release profile.  
 
Sadeghi et al [42] found the tensile strength of the matrix tablets was a critical 
factor for drug release. The results showed the matrices prepared by the water soluble 
drug propranolol hydrochloride and Eudragit RL or RS could not maintain the physical 
dimension for a longer period of time. Addition of Aerosil® 200 increased tensile 
strength of matrices and the tablets could retain their structure which decreased the drug 
release rate. Azarmi et al [29] reported a thermal treating method to modulate the drug 
release from Eudragit® RS and Eudragit® RL matrices. When the matrix tablets were 
heat treated above the glass transition temperature of the polymers, decreased porosity 
was observed and slower drug release was achieved from the Eudragit matrices.  
 
Compared to the hydrophilic matrix tablets, hydrophobic matrix tablets provided 
several advantages [17, 19]: a) suitable for highly water soluble drugs; b) drug release is 
not influenced by the pH and ionic strength of dissolution medium; c) good stability at 
varies moisture levels during storage. The major disadvantage of the hydrophobic matrix 
tablet is the incomplete release of water insoluble drug during the gastrointestinal 
transition time due to the insufficient concentration gradient [43].  To modulate drug 
release from this type of matrix, soluble ingredients such as lactose and PEG are required 
to incorporate into the formulation. The presence of soluble ingredient in the formulation 
helps to form numerous pores in the hydrophobic matrix network for water penetration 
and drug diffusion [44].  
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1.2 Mathematic Models for Matrix System 
 
 
1.2.1 Higuchi equation 
 
In 1961, Higuchi published a mathematical equation to describe drug release from 
matrix systems [11]. Although it was developed to describe the drug release profile from 
the ointment initially, it was later modified to include different geometries and matrix 
characteristics for describing the drug release from matrix tablets [36]. The basic 
equation of Higuchi model is Equation 1-1: 
 
 Qt= ൤S
2Dε
τ ൫2C0-εCS൯CSt൨
1
2
=kt
1
2 (Eq. 1-1) 
 
where Qt is the cumulative amount of drug released in time t; S is the surface area of the 
tablet; D denotes the drug diffusion coefficient in the matrix phase; Cs is the drug 
solubility in the matrix; C0 represents the drug concentration in the matrix; ε is the 
porosity; τ denotes the tortuosity of the matrix; and k is the dissolution rate constant. 
 
Based on this equation, drug release at any given time is proportional to the 
square root of the time. The  release rate constant k are affected not only by the diffusion 
coefficient , surface area and drug solubility in the matrix, but also by the matrix 
properties porosity and tortuosity.  
 
This equation was derived under pseudo steady state assumptions. The 
assumptions include: 
 
 a) Particle size of the drug are small compared to the average diffusion 
distance;  
 b) The diffusion coefficient is constant during the dissolution process;  
 c) Perfect sink conditions are maintained during the dissolution process;  
 d) The only driving force is the diffusion;  
 e) The drug concentration in the matrix is greater than the drug solubility in 
the dissolution medium;  
 f) There is no interaction between drug and matrix, the swelling or 
dissolution of the polymer carrier must be negligible; and  
 g) Only one dimensional diffusion is taken into consideration for the 
equation, the edge effects must be negligible. 
 
Because of the assumption of the steady state diffusion, the Higuchi equation only 
can be used to predict drug release less than 70%. If the percentage of drug release is 
greater than 70%, Higuchi equation cannot give an accurate prediction. 
 
The Higuchi equation is a simple and applicable equation in many cases not only 
for hydrophobic matrix tablet but also in hydrophilic matrix tablet. When it applied for 
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hydrophilic matrix tablet, it is only an empirical equation with square root rate constant 
and could not characterize the system. 
 
 
1.2.2 Power law equation 
 
The power law equation is a semi-empirical equation to describe the drug release 
from polymeric systems. The general equation is [45, 46]: 
 
 Mt/ M∞=k*tn (Eq. 1-2) 
 
where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of 
drug released at infinite time; k is release constant incorporating structural and geometric 
characteristics of the system, and n is the release exponent indicating the mechanism of 
drug release. 
 
This equation is derived by Peppas and co-workers, so it is also called Peppas 
equation. It is a generalization of two independent drug release mechanisms. There are 
Fickian diffusion and Case II transport. In most systems containing swellable polymers, 
the drug release is additive result of polymer relaxation and drug diffusion.  
 
 The release exponent ‘n’ in the power law takes multiple values based on 
geometry of the system. Different values of n for slab, cylindrical and spherical 
geometries and corresponding release mechanisms are listed in Table 1-1. 
 
Take the slab as an example, if the n values < 0.5 , the main mechanism is Fickian  
diffusion; if the n value =1, Case-II transport which is the polymer relaxation is the rate 
limiting process; if n value between 0.5 and 1,  the “anomalous transport” takes place 
where is the combination of both  drug diffusion and swelling of the polymer. 
 
The power law equation is a very simple and useful tool to determine the drug 
release mechanism from the matrix system. It has been successfully applied to many 
matrix systems [47, 48]. Similar as the Higuchi equation, the power law equation is only 
valid for the first 70% of the release profile. However, it is too simple to offer a robust 
prediction for complicated release phenomena. These empirical models can only predict 
the release profile after certain release experiments are conducted and have limited 
capability to predict how the release profiles will change as the chemical or network 
properties of the system are varied. 
 
Scientists have also made some modifications to expand the use of the equation. 
A modification of the power law equation was made by incorporating the concept of lag 
time [49].  
 
 M (t-tlag)/ M∞=k*(t-tlag)n (Eq. 1-3) 
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Table 1-1. Release exponent “n” for devices with different geometry 
 
 
 
 
 
 
  
Slab Cylinder Sphere Release mechanism 
<0.5 <0.45 <0.43 Fickian diffusion 
0.5-1 0.45-0.89 0.43-0.85 Anomalous transport 
>1 >0.89 >0.85 Case transport 
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Another modification was performed by decoupling diffusion and “Case-II 
transport” with the following expression [50]: 
 
 Mt/ M∞=k1*tm + k2*t2m  (Eq. 1-4) 
 
where k1, k2 and m are constants. First term in the right hand of the equation represents 
the contribution of Fickian diffusion (F) to overall drug release and the second term 
represents the contribution of tablet structure relaxation (R). R/F ratio can be calculated 
using Equation 1-5. 
 
 R/F = k2*tm/k1 (Eq. 1-5) 
 
The dominant drug release mechanism can be determined by the R/F ratio at any 
given time during dissolution. The drug release profile can be modulated based on the 
release mechanism. 
 
 
1.2.3 Hopfenberg model 
 
The Hopfenberg model is developed to describe drug release from the degradable 
or erodible drug delivery system [51, 52]. The general equation is: 
 
 Mt
M∞
=1-(1- k0t
C0a
)
n
 ሺEq. 1-6ሻ 
 
where Mt and M∞ are the cumulative absolute amounts of drug released at time t and at 
infinite respectively; k0 is zero order rate constant; C0 denotes the uniform initial drug 
concentration within the system; and a is the radius of a cylinder or sphere or the half-
thickness of a slab; n is a shape factor representing spherical (n = 3), cylindrical (n=2) or 
slab geometry (n = 1). 
 
The model was developed by the following assumptions:  
 
 a) There is no edge and end effect. 
 b) The rate-limiting step of drug release is the surface erosion. 
 c) Time dependent internal or external diffusion resistances do not influence 
matrix erosion. 
 d) Overall kinetics is a zero-order process. 
 
The Hopfenberg model can be applied to a surface eroding polymer matrix system 
with a zero order surface drug detachment. The drug release rate is proportional to the 
surface erosion of the device. 
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1.3 Cellulose Acetate (CA) 
 
 
1.3.1 Chemical structure 
 
Cellulose acetate (CA) is the acetate ester of cellulose. It was produced by the 
reaction of acetic acid and acetic anhydride with purified cellulose in the present of 
sulfuric acid. A further partial hydrolysis was used to remove sulfate and a certain 
number of acetate groups under the controlled conditions. All of the three hydroxyl 
groups located on the repeated unit of cellulose structure can react and form acetate 
esters. The amount of esterfication can be controlled by the reaction conditions. The 
chemical structure of CA is illustrated in Figure 1-1. It contains a cellulose backbone 
which is a repeat unit of anhydrous glucose and connected by β-1, 4 glycosidic linkages. 
The three hydroxyl groups were partially substituted by the acetyl group. The degree of 
the substitution was expressed as the average number of acetyl group in one repeat unit. 
The length of the cellulose chain and the degree of acetyl substitution directly affect the 
physicochemical properties of CA. 
 
 
1.3.2 Physicochemical properties of CA 
 
Cellulose acetate is a tasteless, odorless white powder or pellet. It is generally 
regarded as a nontoxic and nonirritant material. It is hydrophobic in nature and only 
soluble in certain organic solvents such as acetone, methylene chloride-alcohol blends, 
methyl acetate, dimethyl formamide, and dioxane.  The solubility of CA is greatly 
affected by the molecular weight and degree of substitution. 
 
There are various grades of CA available on the market with different molecular 
weight and degree of substitution as listed in Table 1-2. CA polymers have a relatively 
high glass transition temperature 170–190°C and high melting point 230–300°C. The 
glass transition temperature and melting point were increased as increasing the molecular 
weight and degree of substitution of CA. The viscosity of CA polymers listed in       
Table 1-2 was measured in 10% w/v organic solutions. The viscosity of CA polymers is 
directly related to the molecular weight and range from10 to230 mPa.s (10–230 cP). 
Even though there are various grades of CA available, only two of them were approved 
by FDA for pharmaceutical application. There are CA 320S and CA 398-10 NF. 
 
CA polymers were supplied as fine powder or pellet form. For the powder form, 
the typical bulk density is 0.32g/cm3 and typical tap density is 0.4g/ cm3. More than 90% 
of the powder can pass through 80 mesh sieve. These properties make the CA powder 
suitable for direct compression application. The pellet form has to be dissolved in a 
solvent, then form a film after solvent is evaporated. 
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Table 1-2. Physical and chemical properties of different grade of cellulose acetate 
 
aASTM D 871(Formula A) and D 1343 
bNumber average molecular weight in polystyrene equivalents 
  
Figure 1-1.  Chemical structure of cellulose acetate 
CA grades Viscosity
a 
(cP)  
Acetyl 
(%) 
Degree of 
substitution
Hydroxyl 
(%) 
Melting 
range 
Tg °C MWnb
CA-320S 2.4 32.0 1.8 8.7 230-250 180 38,000
CA-398-3 11.4 39.8 2.4 3.5 230-250 180 30,000
CA-398-6 22.8 39.8 2.4 3.5 230-250 182 35,000
CA-398-10NF 38.0 39.8 2.4 3.5 230-250 185 40,000
CA-398-30 114.0 39.7 2.4 3.5 230-250 189 50,000
CA-394-60S 228.0 39.5 2.4 4.0 240-260 186 60,000
CA-435-75S N/A 43.5 2.9 0.9 280-300 185 122,000
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1.3.3 Pharmaceutical application of CA 
 
 
1.3.3.1 Osmotic drug delivery system 
 
The osmotic drug delivery system is a novel delivery system developed in the 
1970s which utilizes osmotic pressure as an energy source to control the drug release. It 
typically consists of the tablet core and a semi-permeable coating layer with a laser 
drilled hole on the coating membrane. The drug release from the osmotic delivery system 
was controlled by the water flux rate, drug solubility and osmotic pressure which 
generated by the osmogent. There are several types of osmotic delivery device on the 
market including: elementary osmotic pump, push–pull osmotic pump, sandwiched 
osmotic pump, liquid oral osmotic system, controlled porosity osmotic pump and 
asymmetric osmotic system. The semi-permeable membrane is an essential part in an 
osmotic delivery system. This membrane should be insoluble and permeable to the water 
to pertain sufficient water flux, but relatively impermeable to the contents inside the 
device to prevent the diffusion of drug and osmogent through the film. It has to be stable 
and rigid enough to retain its integrity during drug dissolution.   
 
CA is the most widely used polymer to form the membrane in osmotic drug 
delivery system due to its excellent mechanical and semi-permeable properties. The 
properties of the membrane are directly related to the water flux rate and therefore affect 
the drug release rate. CA membrane has a relatively high water permeability compared to 
other polymer membranes. The water permeability can be easily be adjusted by the acetyl 
content of the CA, incorporation of plasticizer and the thickness of the membrane. 
 
As the acetyl content increases, the permeability of CA membrane decreases and 
water flux rate also decreases. Yuan et al [53] studied an osmotic pump tablet of 
theophylline by using CA 320S or CA 398-10 NF as a coating membrane. The tablets 
coated with low acetyl content CA (CA-320S) showed higher water permeability and 
faster release rate of theophylline.  
 
Studies have shown the type and the level of plasticizers can alter the properties 
of CA film. In general, incorporation of plasticizer to the CA film lowers the glass 
transition temperature, increases flexibility of film and decreases the strength of the film. 
The water permeability of the CA film depends on the type of the plasticizer used in the 
system. Usually, soluble plasticizers increase the water permeability and insoluble 
plasticizers decrease the water permeability. Guo [54] reported the effect of water soluble 
plasticizer PEG 600 on water permeability and physical properties of CA film. The water 
permeability of CA films decreased as increasing PEG-600 to a minimum level due to the 
antiplasticization effect.  At higher concentration PEG 600, especially when the PEG 600 
is over 30% (w/w), the dramatic increase of water permeability was found owing to the 
plasticizer channels were formed in the CA films. Liu et al [55] studied the effect of the 
nature of the plasticizers on the film properties as well as the drug release rate. Addition 
of hydrophilic plasticizer PEG 200 improved the drug release whereas addition of 
hydrophobic plasticizer triacetin suppressed the drug release from a monolithic osmotic 
 14 
tablet. Films containing PEG as plasticizer developed numerous pores after 24 hours 
dissolution whereas films containing triacetin as plasticizer still remained a dense film 
structure. 
 
The thickness of the coating membrane is another factor that affects the drug 
release from the osmotic system. The water permeability as well as the drug release rate 
is typically inversely proportional to the thickness of the coating membrane. A study [56] 
on nifedipine monolithic osmotic tablet found the drug release rate decreases as the 
thickness of membrane increased from 85-340μm.  But for the asymmetric osmotic 
system, the thickness of the coating membrane was found to have a slight effect on drug 
release rate. This is due to the existence of large numbers of open pores in the membrane. 
The structure of the membrane played a more important role than the thickness [57]. 
 
 
1.3.3.2 Sustained release matrix system 
 
As a water insoluble hydrophobic polymer, CA is widely used in a sustained 
release matrix system. Sustained release matrix tablets prepared by cellulose acetate have 
been investigated by using direct compression or wet granulation methods [38, 58-60]. In 
most of the cellulose acetate matrix tablet formulations, additional binder was added to 
improve the tensile strength of the tablets. The results showed drug solubility is an 
especially important influence on the release rate. The CA matrix is capable of 
controlling the release rate for a sparingly water soluble drug theophylline when a high 
concentration of CA were presented in the tablet. But the satisfactory sustained release 
profiles were difficult to obtain when the drug solubility is higher. This is due to 
insufficient surrounding of CA to highly soluble drug particles. Additional barrier-
coating to the soluble drug particles can effectively prevent the massive drug release and 
matrix erosion.  
 
Another study [61] showed the longer compression dwell time is helpful to 
prolong the drug release from the CA matrix. In order to keep integration of the matrix 
tablet during dissolution, enough bonding caused by the fusion between the polymer 
particles are required. The polymer fusion takes place whiles a temperature higher than 
glass transition temperature of the polymer occurs during tablet compression. For CA 
polymers with high glass transition temperature, a long dwell time and high compression 
pressure are necessary to induce the fusion between the adjacent CA particles.  It was 
concluded that the longer dwell time (>20s) of the compression process was required to 
form bonding by fusion to obtain the sustained drug release profile. But this method is 
not practical for high speed tablet press production. The production rate will be very 
limited if a long compression dwell time is applied. 
 
Yuan et al [58] studied the formulation effect on the drug release from the 
cellulose acetate (CA) or cellulose acetate butyrate (CAB)  matrix tablet prepared by 
direct compression process. It was concluded drug solubility, polymer concentration, type 
and degree of substitution of polymer, and other excipients presented in the matrix tablets 
are the key formulation factors. It was found that the tablet prepared by the more 
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hydrophobic polymer CAB showed slower drug release rate than CA. This research also 
found admixing the plasticizer triethyl citrate (TEC) with CA can help to retard drug 
release from the matrix tablet. 
 
CA is also used for preparation of matrix microspheres [62-64]. The low bulk 
density and hydrophobic nature make CA suitable in preparation of a gastric floating 
system. The smooth and spherical microspheres can be obtained by using CA as a carrier 
material with encapsulation efficiency ranging from 73% to 98%. The microspheres 
sustained the drug release and remained floating for over 10 hours. The drug release rate 
from the microsphere decreased as the mean particle size and the concentration of the 
polymer increased [63]. 
 
 
1.3.3.3 Other applications 
 
As an odorless and tasteless polymer with excellent film properties, CA is also 
used for the taste masking application [65, 66]. When CA based coating was applied on 
the surface of acetaminophen granules, the unpleasant bitter taste of acetaminophen 
diminished. A taste masked chewable tablet can be obtained by compressing these 
granules with other excipients. Yu et al [66]coated the  levofloxacin particles by using  
the combination of CA and other pH sensitive polymer Eudragit® E-100. The improved 
palatability of drug was obtained. These taste masked drug particles were suitable for oral 
liquid dosage form.   
 
CA film can be used as rate controlling membrane for transdermal delivery 
system [47, 67]. The smooth and flexible film can be prepared by using CA and 
plasticizer. The plasticized films are permeable for both water vapor and drug. The 
permeability coefficient of the drug is dependent on the type of plasticizer and the 
thickness of the film. High permeability coefficient was observed when water soluble 
plasticizer was applied. Drug diffusion rate increased as thickness of the film decreased. 
The drug diffusion from the film can be prolonged and followed zero order kinetics. 
Incorporation of water soluble polymer PVP into the CA film decreased the tensile 
strength of the film and increased film permeability, but did not alter the drug diffusion 
kinetics. 
 
 
1.4 Application of Plasticizers on Oral Solid Dosage Form 
 
Plasticizers are typically low molecular weight compounds which are capable of 
penetrating into the polymer structure and making them soft and flexible. The process of 
adding a plasticizer or heat to soften the material and makes it more plastic is called 
plasticization. The plasticization was applied in several of pharmaceutical process 
including film preparation, hot melt extrusion and matrix tablet preparation to improve 
the process condition or/and achieve better functionality.  
 
The plasticization is occurred by the intermolecular interaction between the 
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plasticizer and the polymer. This interaction increases the free volume between the 
polymer chains and ease of movement of polymer chains could be dramatically 
increased. Thus both of the glass transition temperature and the melting viscosity of the 
polymer decreases after plasticization. The interaction of polymer and plasticizer also 
help to lower the melting energy of the semi-crystalline polymers and facilitate the 
fusion.  
 
The purpose of incorporation of plasticizer into the film formulation is to improve 
the mechanical properties and modify drug release behavior. The plasticizer typically 
increases the elongation and elastic modulus of film. Addition of plasticizer can prompt 
to film formation, reduce the brittleness, improve the flexibility and plasticity and 
increase the mechanic resistance of the film. Lower water permeability and oxygen 
transition rates were observed for plasticized film. The drug release rate from the film or 
the film coated pellets can be modulated by the addition of the plasticizer. In general, 
hydrophilic plasticizer accelerates the drug release and hydrophobic plasticizer 
suppresses the drug release. 
 
Application of the plasticizer in the hot-melt extrusion process often lowers the 
process temperature and improves the process condition. With the help of the plasticizer, 
a hot-melt extrusion process can be performed at lower temperatures to avoid the 
decomposition of the drug and the polymer. Since the decreased viscosity of the polymer 
can be obtained after addition of the plasticizer, less energy is required for the process 
and the process condition is improved. 
 
The application of the plasticizer in sustained release tablets has been reported by 
several scientists. Hardy et al [68] studied the plasticizer effect on the compression 
properties of an HPMC matrix tablet. Except for water soluble plasticizer propylene 
glycol, addition of other plasticizers especially hydrophobic plasticizer decreased the 
tensile strength of the tablets and increased elasticity of the tablets. Yuan et al [58] 
admixed the plasticizer with CA to modify theophylline release from the  hydrophobic 
matrix tablet. The rate of release of theophylline decreased after addition of the 
plasticizer TEC. Xiao [69] investigated the plasticizer effect on the sustained release 
matrix tablets prepared by ethyl cellulose. It was found addition of the plasticizer 
decreased porosity of the tablet, thus the drug release rate was also decreased. The slower 
drug release rate was observed for the tablets prepared with more concentrated and 
hydrophobic plasticizer. 
 
As a plasticizer for pharmaceutical application, the following properties are 
required: 
 
 a)  Good plasticization efficiency  
 b)  Non toxic  
 b)  Compatible with drug and polymer 
 d)  Nonvolatile and stable in the storage condition 
 e)  Regulatory acceptance 
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The commonly used pharmaceutical plasticizers and their physicochemical 
properties are listed in Table 1-3. They have been investigated as plasticizers in different 
pharmaceutical processes to demonstrate a good interaction with the polymers and a good 
safety profile. 
 
 
1.5 Co-processed Excipients for Oral Solid Dosage Forms 
 
 
1.5.1 Excipient for oral solid dosage form 
 
All the oral solid dosage forms consist of active pharmaceutical ingredients (API) 
and excipients. Historically, excipients has been viewed as merely inert additives and not 
been given the credit for their effect on the finished pharmaceutical dosage form. But the 
importance of the excipients has been realized in recent years. In fact, the fate of a drug 
product can be determined by the functionality of the excipient. The major contributions 
of excipient to the end product include: 1) improving the process condition during 
manufacturing [70]; 2) improving the physicochemical properties of API and enhancing 
the stability and bioavailability; 3) modulating the drug release characteristic in the body 
and improve the patient acceptability; 4) facilitating administration; 5) aiding product 
identification; 6) attributing to overall safety and effectiveness.  
 
The tablet is the most preferred dosage form among all oral solid dosage forms. 
This is due to the precise dosing, cost effective manufacturing and good patient 
compliance. The principal excipients in a tablet formulation include filler, binder, 
disintegrant, lubricant, glidant and coating material. In-depth knowledge of 
physicochemical properties of excipients and numerous pharmaceutical tests are required 
while selecting the right excipient for a tablet formulation. Excipients with multiple 
functions leading to less complicated formulation as well as time and cost effectiveness 
are more preferred to be selected by pharmaceutical formulators. 
 
Tablets are manufactured by either granulation or direct compression. Direct 
compression is simpler and less expensive process because multiple granulation 
processes were avoided. But it has specific requirement for the properties of the raw 
materials such as good flowability, good compactability, less segregation potential, low 
lubricant sensitivity and good machineability in a high speed tablet press. For most of the 
tablet formulations (70-80%), the concentration of the excipients are higher than the 
active drug. Therefore, excipients play a major role for direct compression formulations 
[6, 71]. In order to reduce the development process and get the product to the market 
faster, there is an increasing demand for multi-functional excipients for direct 
compression formulations. 
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Table 1-3. Physical and chemical properties of commonly used pharmaceutical 
plasticizers 
 
 
 
 
  
Plasticizers 
Boiling point 
 (ºC) 
Water solubility 
(g/100 ml) @ 25ºC Log P 
Triethyl Citrate (TEC) 288 5.5 1.493 ± 0.570 
Acetyltriethyl Citrate (ATEC) 294 0.7 3.731 ± 0.641 
Tributyl Citrate (TBC) 322 <0.1 4.681 ± 0.571 
Acetyltributyl Citrate (ATBC) 326 <0.1 6.919 ± 0.641 
Dibutyl Sebacate (DBS) 345 <0.1 5.975 ± 0.228 
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1.5.2 The source of new excipient 
 
The improved functional excipients typically come from new chemical entities, 
new grades of existing materials or a new combination of existing materials [10, 72]. 
Development of a new chemical entity is usually a high risk and large investment. It must 
undergo a very long cycle with various stages of regulatory approval for assessment of 
safety and toxicity [10, 71]. The approval of new excipients is even more complicated 
than a new drug product. It is a very time and money consuming process. Successful new 
grades of the existing excipients can be obtained by the chemical modification such as the 
pregelatinized starch, croscarmellose, and crospovidone, or by particle engineering such 
as spray dried lactose, Avicel ®101,102, 200 (Microcrystalline cellulose), Methocel® 
DC (direct compressible HPMC). It has been a very successful approach for developing 
new excipients over last three decades. But the extent of functional improvement is very 
limited because of the restricted range of possible modification. A new combination of 
the existing excipients is another good choice because most tablet formulations currently 
consist of multiple excipients. A large number of excipient combinations are available for 
improving the performance of the existing excipients. Two development processes of the 
new combinations are typically involved. They are physical mixing and co-processing. 
The most successful physically mixed excipient on the market is Opadry®. It is a pre-
blended dry powder coating formulation. It combines polymer, plasticizer and pigment to 
provide a one-step coating formula. Kollidon® SR is another example of a combination 
of mixed excipients. It contains polyvinyl acetate and polyvinyl pyrrolidone at ratio 80:20 
and is used for sustained release matrix tablets. The co-processed excipient is combined 
at a subparticle level of excipients. This is much broader platform for improving the 
functionality of the existing excipients and has gained more attention over the years. 
 
 
1.5.3 Co-processed excipient 
 
The International Pharmaceutical Excipients Council (IPEC) defines a co-
processed excipient as follows: “A co-processed excipient is a combination of two or 
more compendial or non-compendial excipients designed to physically modify their 
properties in a manner not achievable by simple physical mixing and without significant 
chemical change” [72]. Co-processed excipients contain two or more excipients and 
possess the performance advantages over the physical mixture. Not only improved 
performance but also reduction of undesired properties of a single excipient can be 
achieved by using co-processing. The co-processing excipients are typically produced by 
the commercially available pharmaceutical manufacture processes, such as wet 
granulation, dry granulation, spray drying and freeze drying. Spray drying is the most 
commonly used method and it is very simple and effective. Most importantly, it can 
incorporate one excipient into another excipients’ particle structure and provide desirable 
physical advantages. 
 
The typical process of developing a co-processed excipient includes the following 
steps [73]: a) identify the functionality requirements and select the appropriate excipients; 
b) determine the ratio of various excipients; c) select the suitable co-process method such 
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as spray dry, wet granulation; d) optimize the preparation process; e) evaluate the 
physicochemical properties and functionality of the co-processed excipient. 
 
The particle properties of excipients such as particle size, particle size distribution, 
powder porosity and surface roughness can be modified by co-processing, thus improve 
the functionality of the excipients including improved flowability, better compactability 
and reduced segregation potential. These improved properties of an excipient make it 
more suitable for direct compression formulations. The major benefits of the excipients 
received from the co-processing were summarized as [73]: a) lack of chemical change; b) 
reducing the number of excipients in one formulation; c) improved physical mechanical 
properties such as flowability and compactability; d) better dilution potential and less 
segregation potential; e) less lubricant sensitivity. 
 
There are several co-processed excipients for immediate release formulation 
available on the market as listed in Table 1-4. The improved manufacturing efficiency 
and reduced cost of the final drug product can be obtained by using these co-processed 
excipients. 
 
 
1.5.4 New excipients in sustained release application 
 
A sustained release matrix tablet is the simplest and the most cost effective 
delivery system for modulating the drug release behavior in the body. The market of 
sustained release tablets keeps increasing every year, but the development of new 
excipients is relatively slow. There are only two new sustained release excipients coming 
to the market in the last few decades.  
 
One is Methocel® DC which was developed by Dow Chemical. It is a new grade 
of HPMC polymers customized for direct compression application. The DC grade of 
HPMC can achieve better flowability without comprising the sustainability and 
compactability by strictly controlling the particle size distribution [74]. The other one is 
Kollidon® SR which developed by BASF. It is a physical mixture of polyvinyl acetate 
and polyvinyl pyrrolidone at ratio 80:20. Kollidon® SR can be used for both granulation 
and direct compression process. The water soluble components polyvinyl pyrrolidone can 
gradually leaches out from the matrix during dissolution thereby modulating the drug 
release from the hydrophobic matrix system [75]. 
 
Beside the commercial available excipients, Xiao [69] developed a co-processed 
excipient consisting of ethyl cellulose, plasticizer and fillers by a wet granulation method. 
This excipient showed good flowability and compactability and can be used for 
preparation of a hydrophobic matrix tablet. But this hydrophobic matrix tablet is only 
suitable for the drugs with low water solubility. For highly water soluble drug, a 
compression coating has to be applied to obtain a desired in vitro release profile. 
 
In our study, we have developed a co-processed sustained release excipient 
utilizing a cellulose acetate with plasticizer and other filler via various preparation  
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Table 1-4.  Commercial available co-processed excipients 
 
Ingredients of 
co-processed 
excipients 
Trade name Manufacturer Improved functions 
Lactose,  
Kollidon 30, 
Kollidon CL 
Ludipress BASF  
 
Low degree of 
hygroscopicity, good 
flowability, tablet hardness 
independent of machine speed 
Mannitol, 
Kollindon 
CL,PVA 
Ludiflash BASF 
Less hydroscopicity, directly 
compressible, good flowability, 
resulting hard tablet with lower 
friability 
Lactose, 
Lactitol 
Pharmatose 
DCL 40 DMV 
Good flowability, high dilution 
potential, lower water uptake at 
high humidity  
Lactose, 
cellulose Cellactose Meggle 
Highly compressible, good 
mouth-feel, better tableting 
at low cost 
Lactose,  
MCC Microcelac Meggle 
Good flowability and binding 
properties, less lubricant 
sensitivity 
MCC,  
silica dioxide Prosolv JRS Pharma 
Better flow, tablet strength and 
less lubricant sensitivity 
MCC, Mannitol Avicel HFE 102 
FMC 
Biopolymer 
Better tablettability at  slower 
tablet speed, less lubricant 
sensitivity 
MCC, Guar 
gum 
Avicel CE-
15 
FMC 
Biopolymer 
Smoother ,creamier mouth feel, 
less tooth-packing 
MCC, Na CMC Avicel CL-611 
FMC 
Biopolymer Increase formulation stability 
Starch, Lactose StarLac Roquette 
Good flowabililty and 
compactability with rapid 
disintegration time 
Kollindon VA 
64, 
 Plasdone S 630 
Copovidone BASF Good flowability and binding properties 
Sugar, dextrin Di-Pac Domino 
Good flowability, low 
hygroscopicity, direct 
compressible 
MCC, 
crospovidone, 
HPMC 
PanExcea 
MHC300G  Avantor 
Good flowability, compactability 
with rapid disintegration for 
immediate release tablet 
Mannitol, 
calcium silicate 
PanExcea 
MHC200G Avantor 
Good flowability, compactability 
with rapid disintegration for oral 
disintegrating tablet 
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methods. This co-processed excipient is designed to be used for directly compressed 
sustained release matrix formulation and is suitable for both water soluble and insoluble 
drugs. 
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Chapter 2. Preparation of Co-processed Plasticized Cellulose Acetate Excipient and 
Evaluation of the Physical and Compaction Properties 
 
 
2.1 Introduction 
 
A significant growth of the oral drug delivery system market was observed over 
the last decade. According to the GBI’s research, it will maintain an 11.3% annual 
growth rate till 2016 [76]. A sustained release matrix tablet is one of the major 
components in the oral drug delivery system. This is the simplest and the most cost 
effective dosage form for modulating the drug release behavior in the body. The 
manufacturing process for sustained matrix tablets is similar to that of traditional tablets. 
The common preparation methods are wet granulation, dry granulation and direct 
compression. Among these methods, the direct compression method is the simplest and 
requires less unit processes. But it has specific requirements for the properties of the 
powder such as flowability, compactability. For most of the tablet formulations (70-
80%), the concentration of the excipients are higher than the active drug. Therefore, 
excipients play a major role for direct compression formulation [6, 71]. In order to reduce 
the development process and get the product to the market faster, there is a market 
demand for multi-functional excipients for direct compression formulation development 
of sustained release matrix tablets. 
 
The improved functional excipients typically come from new chemical entities, 
new grades of existing materials or a new combination of existing materials [72]. 
Development of a new chemical entity is usually a high risk and large investment. It must 
undergo various stages of regulatory approval for assessment of safety and toxicity [71] 
which is a time and money consuming process. Successful new grades of the existing 
excipients can be obtained by the chemical modification such as the pregelatinized starch, 
croscarmellose, and crospovidone, or by particle engineering such as spray dried lactose, 
Avicel ®101,102, 200 (Microcrystalline cellulose), Methocel® DC (direct compressible 
HPMC). It has been a very successful approach for developing new excipient over last 
three decades. But the extent of functional improvement is very limited because of the 
restricted range of possible modification. A new combination of the existing excipients is 
another good choice because most tablet formulations currently consist of multiple 
excipients. A large number of excipient combinations are available for improving the 
performance of the existing excipients. Two development processes of the new 
combinations are typically involved. They are physical mixing and co-processing. The 
most successful physically mixed excipient on the market is Opadry®. It is a pre-blended 
dry powder coating formulation. It combines polymer, plasticizer and pigment to provide 
a one-step coating formula. Kollidon® SR is another example of a combination of mixed 
excipients. It contains polyvinyl acetate and polyvinyl pyrrolidone at ratio 80:20 and used 
for sustained release matrix tablets. The co-processed excipient is combined at a 
subparticle level of excipients. This is much broader platform for improving the 
functionality of the existing excipients and has gained more attention over the years. 
 
The International Pharmaceutical Excipients Council (IPEC) defines a co- 
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processed excipient as follows: “A co-processed excipient is a combination of two or 
more compendial or non-compendial excipients designed to physically modify their 
properties in a manner not achievable by simple physical mixing and without significant 
chemical change”. Co-processed excipient contains two or more excipients and possesses 
the performance advantages over the physical mixture. Not only improved performance 
but also reduction of undesired properties of a single excipient can be achieved by using 
co-processing. The co-processing excipients are typically produced by the commercially 
available pharmaceutical manufacture processes, such as wet granulation, dry 
granulation, spray drying and freeze drying. Spray drying is the most commonly used 
method and it is very simple and effective. Most importantly, it can incorporate one 
excipient into another excipients’ particle structure and provide desirable physical 
advantages. 
 
Several co-processed excipients for immediate release formulation are available 
on the market. The improved manufacturing efficiency and reduced cost of the final drug 
product can be obtained by using the co-processed excipient. But there is no 
commercially available co-processed excipient for sustained release matrix formulation. 
In our study, we have developed a co-processed sustained release excipient utilizing a 
hydrophobic polymer with plasticizer and other filler via various preparation methods. 
This co-processed excipient is designed to be used for directly compressed sustained 
release matrix formulation. 
 
The hydrophobic polymer we selected in our study is cellulose acetate (CA). It is 
an extensively used polymer in pharmaceutical applications. Because of the hydrophobic 
nature and good film properties of the CA, it is potentially a good polymer candidate for 
sustained release matrix tablets. Sustained release matrix tablets prepared by cellulose 
acetate have been investigated by using direct compression or wet granulation methods 
[58, 61]. The results show that for a sparingly soluble drug theophylline, a large amount 
of CA was required to achieve the desired sustained release profile. It was difficult to 
formulate a highly water soluble drug by using CA as the retarding agent. Some studies 
concluded that CA is very sensitive to the solubility of the drug and it is not suitable for 
retarding the release for highly water soluble drug. 
 
The purpose of our study is to modify the physical characteristic of the CA by 
using co-processing technique and increasing the ability of cellulose acetate for 
controlling the drug release rate for drugs of varying solubility. This chapter is focused 
on the preparation and physical characterization of this novel co-processed excipient. 
 
 
2.2 Materials and Methods 
 
 
2.2.1 Materials 
 
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF, 
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate 
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(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate 
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Regular dicalcium 
phosphate dihydrate (DCP, Rhodia Inc., Blue Island, IL) and milled dicalcium phosphate 
dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler. Magnesium 
stearate (Mallinckrodt, Paris, KY) was used as a lubricant. 
 
 
2.2.2 Methods 
 
 
2.2.2.1 Co-processed methods 
 
Three different methods including heat treatment, wet granulation and spray 
drying were investigated for preparing the co-processed excipients. The formulations of 
the co-processed excipients were listed in Table 2-1. We selected ATEC as a hydrophilic 
plasticizer in F1 and ATBC as a hydrophobic plasticizer in F2. For comparison, we also 
prepared formulation F0 which doesn’t contain any plasticizer. 
 
A heat treatment method is the simplest preparation method in this study.  CA 
was mixed with appropriate amount of plasticizer in a mortar and pestle. This mixture 
was treated in the 100° C oven for 12 hours. The heat treated CA and plasticizer mixture 
was further mixed with regular DCP in a twin shell blender (Patterson-Kelley Co, East 
Stroudsburg, PA) for 3 minutes. 
 
The wet granulation method was performed in a high shear granulator (Collete 
MICROGRAL, Niro Inc., Columbia, MD). Appropriate quantities of CA were mixed 
with the milled DCP at impeller speed 1000 rpm for 1 minute. The plasticizer was 
dissolved into acetone-isopropyl alcohol (70:30, v/v) solution. The liquid mixture was 
added to the powder bed by a peristaltic pump at speed of 20g/min. The liquid mixed 
with the powder at impeller speed of 1000 rpm and chopper speed of 4000 rpm for 2 
minute to obtain the wet mass. The wet mass was dried in an oven dryer at 60°C for 2 
hours to remove the solvent. The dried granules were passed through a 20 mesh sieve to 
remove the large agglomerates. 
 
The spray drying method was performed at lab scaled mini spray dryer B295 
(Buchi, Switzerland). CA was dissolved in acetone: isopropyl alcohol (50:50) solution at 
the concentration of 3%. An appropriate amount of plasticizer was added in this solution. 
The milled DCP was suspended in the solution using a magnetic stirrer. This suspension 
was spray dried while stirring. Operation parameters are as following: Inlet temperature: 
80°C; outlet temperature 36-50°C; aspirator: 60%; air volume: 40ml and pumping rate: 
50%. The resulting powders were kept in vacuum oven at 60 °C for 12 hours to remove 
the excess solvent and then compressed into the 13mm tablets under the compression 
force of 0.3 metric ton by using the Carver press. The co-processed granules were 
obtained by passing the large tablets through a 20 mesh sieve. In order to investigate the 
effect of formulation factors on the physical properties of the co-processed excipient, the 
formulations containing different plasticizers and different concentration of plasticizer 
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Table 2-1. Formulations of the co-processed excipients for three preparation 
methods 
 
Ingredients  Percentage (%) F0 F1 F2 
CA 398-10 NF 20 20 20 
ATBC 0 0 10 
ATEC 0 10 0 
DCP 80 70 70 
Total  100 100 100 
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were prepared by spray dried method and listed in Tables 2-2 and 2-3. 
 
 
2.2.2.2 Bulk density, tap density and Carr’s index evaluation 
 
Fill the dry granules in a 50ml graduated cylinder to approximately 40ml, record 
the weight and bulk volume. The cylinder was tapped on a tap device (Vankel Industrails, 
Edison, NJ) for 100, 200, 300, 400 times until a constant volume was achieved. This 
volume was recorded as the tap volume. The bulk density (g/ml) was calculated by      
Equation 2-1. The tap density was calculated by Equation 2-2 and the Carr’s index was 
calculated by Equation 2-3.  
 
 Bulk density= Weight of the sample (g)/ Bulk volume (ml) (Eq. 2-1) 
 
 Tap density= Weight of the sample (g)/ Tap volume (ml) (Eq. 2-2) 
 
 Carr’s index=100*(Tap density-Bulk density)/ Tap density (Eq. 2-3) 
 
 
2.2.2.3 Powder porosity evaluation 
 
The true density of the powder was measured by a helium pycnometer (AccuPyc 
1330, Micromeritics, Norcross, GA). Powder porosity was calculated from the Equation 
2-4. 
 
 Powder porosity (%) = (1 - bulk density/true density)*100 (Eq. 2-4) 
 
 
2.2.2.4 Particle size analysis 
 
The particle size distribution was evaluated by sieve analysis.  This experiment 
was performed on the Gilsonic Autosiever (Gilson Company Inc, Lewis Center, Ohio) for 
7 minutes at amplitude of 5mm. The mesh size of the sieve used in this study were 
20(850μm), 35 (500 μm), 60 (250 μm), 80 (180 μm), 120(125 μm), 140(106 μm) and 
200(75 μm). Approximately 10g of granules was used for analysis. The geometric mean 
particle size was calculated by Equation 2-5. 
 
 Dgw = log–1 [(Σ (Wi *log Di)/ ΣWi] (Eq. 2-5) 
 
where Dgw is the geometric mean particle size, Wi is the weight of the granules stayed on 
the i th sieve, Di is the diameter of the i th sieve in the stack. 
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Table 2-2.  Formulations of the co-processed excipients prepared from different 
plasticizers 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-3. Formulations of the co-processed excipients prepared from different 
concentration of plasticizers 
 
Ingredients  Percentage (%) F0 F2 F5 F6 
CA 398-10 NF  20 20 20 20 
ATBC 0 10 2.5 5 
Milled DCP 80 70 77.5 75 
Total  100 100 100 100 
  
Ingredients Percentage (%) F0 F1 F2 F3 F4 
CA 398-10 NF  20 20 20 20 20 
ATEC 0 10 0 0 0 
ATBC 0 0 10 0 0 
TEC 0 0 0 10 0 
DBS 0 0 0 0 10 
Milled DCP 70 70 70 70 70 
Total  100 100 100 100 100 
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2.2.2.5 Powder flowability evaluation 
 
In order to provide an overall evaluation of the powder flowability, a weighted 
composite index was used [77]. It can be calculated by Equation 2-6. The three 
parameters (critical orifice, Carr’s index and angle of repose) in this equation all 
contribute to 1/3 of the overall flowability. The highest value of the composite index is 
100. If the value is greater than 70, the sample can be considered to have a good 
flowability. Carr’s index was calculated by Equation 2-3. Critical orifice was measured 
by using a Flowdex (Hanson Research, Chatsworth, CA) and the angle of repose was 
measured by funnel method.  
 
 Composite index = -10/9*critical orifice +340/9 + (- 2/3*Carr’s Index) 
  +110/3+ (-2/3* angle of repose) +50 (Eq. 2-6) 
 
 
2.2.2.6 Specific surface area measurement 
 
Specific surface area of all the batches was determined by the nitrogen gas 
adsorption method. The weighed sample was first degassed at 40°C under nitrogen gas to 
remove moisture and contamination. The surface area of the degassed sample was 
measured by the Gemini Surface Analyzer (Micromeritics, Norcross, GA) using nitrogen 
gas as absorption gas source. The multipoint BET (Brunauer, Emmett and Teller) 
equation was used for calculation. 
 
 
2.2.2.7 Scanning electron microscopy (SEM) study 
 
SEM was used to characterize the powder morphology. The powders were first 
coated by 10nm gold on the surface for improving the conductivity, and then were 
examined by the FEI XL-30 Scanning Electron Microscopy. (FEI, Hillsboro, OR). 
 
 
2.2.2.8 Compactability evaluation 
 
The compactability of the co-processed excipients was evaluated by the 
compression profile and the Heckel plot.  The co-processed excipient was first mixed 
with 0.5% magnesium stearate in a twin shell blender (Patterson-Kelley Co, East 
Stroudsburg, PA) for 2 minutes, and then was compressed into 400 mg tablets at 
compression forces of 0.3, 0.5, 0.8, 1.0, and 1.5 metric ton by using a 3/8 inch flat faced 
tooling on a Carver press (Carver Inc., Wabash, IN) . The dwell time was maintaining 3 
seconds for all the batches. Five tablets were prepared for each batch. Hardness of the 
resulting tablet was measured by a PTB 311 hardness tester (PharmaTest, Germany). The 
tensile strength of tablets was calculated from the Equation 2-7. 
 
 Tensile strength=2*hardness/πDl (Eq. 2-7) 
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where D is the tablet diameter and l is the tablet thickness. 
 
The Heckel’s plot [78, 79] for the co-processed excipient was constructed by the 
Equation 2-8. 
 
 ln(1/(1 − D)) = kP + A (Eq. 2-8) 
 
where D is the relative density of a powder column at pressure P, k is the slope. A is a 
constant. The slope of the Heckel’s equation can be used to calculate the yield strength as 
Equation 2-9. 
 
 Y = 1/ k (Eq. 2-9)  
 
The lower yield strength indicates less amount energy is required for plastic 
deformation. 
 
 
2.2.2.9 Glass transition temperature (Tg) measurement 
 
A cast film method was used to prepare film samples. CA 398-10 NF was 
dissolved into acetone solution at a concentration of 10%. Appropriate amount of 
plasticizer was added to the solution and mixed uniformly with the 10 % CA solution. 
Thereafter, 1ml of the solution was transferred to a Teflon Petri dish and dried at 60°C in 
vacuum oven for 24 hours to remove the solvent. The Differential Scanning Calorimeters 
(DSC) (TA instruments, New Castle, Delaware) was used to determine the Tg of the film. 
Conventional modulate DSC program was employed in this study. The heating rate is 20 
°C/ min and the heating range is 30°C to 220°C. The TA Universal V 4.4A software was 
used to analyze the data. 
 
 
2.3 Results and Discussion 
 
 
2.3.1 Effect of different process methods  
 
 
2.3.1.1 Morphology 
 
The SEM image of the raw material as well as the co-processed excipients was 
shown in Figure 2-1. Since the images of F0, F1 and F2 for each process method are 
similar, we only selected F2 as an example. The original CA has the irregular particle 
shape and the rough surface. After it mixed with the plasticizer ATBC and heated for 12 
hours in the oven, as shown in Figure 2-1B, the particle shape and the surface structure 
remained similar to the original CA. This indicates the plasticizer is only physically 
adsorbed on the surface of CA or penetrates into the small pores in the CA particles. 
Strong interaction between the polymer and the plasticizer was not observed. For the wet 
 31 
 
 
 
 
 
 
A: Original cellulose acetate 398-10 NF; B: CA mixed with ATBC at 2:1 ratio and heat 
treated for 12hours; C: milled Dicalcium phosphate; D: co-processed F2 granules by 
using wet granulation method; E: spray dried powder of F2 formulation; F: dry granules 
of spray dried F2.  
Figure 2-1. SEM image of the excipient 
A B
C 
E 
D
F
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granulation process, the starting materials are milled DCP and CA mixture, the milled 
DCP exhibit a long prism crystalline structure under the SEM. These crystalline 
substances agglomerated with the CA particles after the wet granulation. The crystalline 
structure remains the same at the final granules as shown in Figure 2-1D. The original 
CA particle in the agglomerate is hard to identify because of the interaction with wet 
agent which contains the plasticizer during wet granulation. The CA particles dissolved 
or partially dissolved in the wetting agent and formed the liquid bridges which remain 
between the solid particles. This liquid bridge will be solidified once particles are dried. 
The original shape and surface of CA particles were changed and a new shape and 
surface were generated.  Figure 2-1E showed the spray dried mixture of CA, milled DCP 
and plasticizer. In this mixture, CA was presented as a film form. These films remained 
on the surface of the milled DCP or in an individual small piece. The plasticizer 
completely interacted with CA and remained inside the CA film. The crystalline structure 
of DCP was totally covered by the plasticized CA film. The particle size of the spray 
dried powder was increased after dry granulation, but the film form of plasticized CA did 
not change in the agglomerate as shown in Figure 2-1E.  
 
 
2.3.1.2 The physical characteristics 
 
The physical properties of the co-processed excipients are influenced by the 
preparation methods as shown in Table 2-4. For the excipients prepared by the heat 
treatment method, the three formulations exhibit similar bulk density, tap density and the 
mean particle size. The only physical difference was observed from the powder porosity. 
The two formulations with plasticizer showed lower porosity than the formulation 
without plasticizer. This is because the plasticizer only remained on the polymer surface 
and did not change the size and surface of the polymer as illustrated in Figure 2-1B. The 
porosity decrease is due to the liquid plasticizer which filled the pores of the polymer 
powder. For the excipients prepared by wet granulation method, addition of the 
plasticizer decreases the bulk density, taps density and increases the powder porosity. 
These differences can be explained by two factors. Firstly, the interaction of the 
plasticizer and polymer results in a stronger and smoother film, therefore less particle 
interlock appears in the processed excipient. Secondly, the density of liquid plasticizer is 
less than the solid DCP. This contributes to a lower bulk density and tap density. The 
excipients prepared by the spray dried methods showed similar physical properties. This 
process method is very powerful and totally changed the physical properties of the 
original polymer. The resulting new physical form was not affected by the addition of the 
plasticizer and the type of the plasticizer. Among the three preparation methods, the heat 
treatment method and wet granulation method generate more density and less porous 
excipients and the spray dried method generates light and porous excipients. The particle 
size of the excipients prepared by spray dried method and wet granulation method are 
larger than the heat treatment method. This is because the agglomerates formed in those 
two processes. 
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Table 2-4. Physical properties for the co-processed excipient prepared by three 
different methods 
 
 
 
 
  
Formulations 
Bulk 
density 
(g/ml) 
Tap 
density
(g/ml) 
Carr’s 
index 
(%) 
Powder 
porosity 
(%) 
Geometric 
mean 
particle 
size ( µm)
F0 (Heat treatment) 0.67 0.79 15.75 69.16 196.34 
F1 (Heat treatment) 0.66 0.80 14.78 65.93 204.51 
F2(Heat treatment) 0.67 0.82 17.74 65.04 205.85 
F0(Wet granulation) 0.77 0.88 18.61 63.50 299.82 
F1(Wet granulation) 0.68 0.79 12.88 67.11 277.54 
F2(Wet granulation) 0.63 0.77 13.54 68.46 287.71 
F0(Spray dried) 0.52 0.68 21.11 73.88 249.36 
F1(Spray dried) 0.55 0.73 23.42 73.40 261.44 
F2(Spray dried) 0.54 0.69 22.00 72.60 247.16 
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2.3.1.3 Flow characteristics 
 
The flowability of the co-processed excipients is listed in Table 2-5. All the co-
processed excipients prepared in this study showed good flowability, the flowability  
composite index all greater than 70. The flowability results suggested that the flowability 
of the co-processed excipients was only affected by the preparation method and that the 
formulation factors including addition of plasticizer and the type of plasticizer did not 
affect the powder flowability. The excipients prepared by heat treatment method and wet 
granulation method showed better flowability than the spray dried method. The large 
amount of fine powders existing in spray dried excipients as shown in Figure 2-1E is 
responsible for the smaller flowability index. 
 
 
2.3.1.4 Compactability  
 
 
2.3.1.4.1 Compression profile 
 
The compression profile of all the co-processed excipients was shown in     
Figure 2-2. The co-processed excipients prepared by spray dried method exhibit the best 
compactability and form the strongest tablets. Followed by the wet granulation method, 
poor mechanical strength was observed from the tablets prepared from the heat treatment 
co-processed excipients. Even at highest compression pressure, the tensile strength of 
both formulation F1 and F2 are smaller than 1.0. This poor mechanical strength may 
result in tablet breakage during rigorous handling and transportation.  In all the 
preparation methods, addition of the plasticizer decreased the tensile strength of the 
tablets due to the soften effect of the plasticizer on the polymer. The type ATEC produces 
stronger tablets than the hydrophobic plasticizer ATBC for all three preparation methods. 
The compactability difference can be explained by the surface area results (Table 2-6). 
For plastic deformation material CA, it will only undergo plastic deformation and won’t 
generate new surface during compression. The tensile strength of final tablet is directly 
related to the surface area of the material. The bigger surface area of the material, the 
more chance for the particles connect to each other to form solid bonding and yield 
stronger tablet. In our study, we found the linear relationship between the surface area 
and the tensile strength of the tablets at the compression force of 1.5m ton. (R2=0.94)   
Typically, plasticizer can penetrate to the polymer structure and make the polymer more 
flexible and have better mobility. Therefore, the smoother surface will be expected when 
we mix plasticizer with the polymer. The smooth surface has less surface area compare to 
the irregular surface. If the plasticizer doesn’t interact very well with the polymer, only 
one part of the plasticizer molecules enters the polymer structure and other part remains 
outside of the polymer structure, the surface area of the polymer will even less because 
the excess liquid filled all the void space of the surface. The surface area results indicate 
the plasticizer ATEC has a better interaction with CA than ATBC. This result was 
consistence with the result of glass transition temperature. In this study, the co-processed 
excipient prepared by spray dried method exhibit high powder porosity and large surface 
area. Without the plasticizer, the wet granulated excipient has similar surface area to the 
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Table 2-5. Flow properties for the co-processed excipient prepared by three 
different methods 
 
 
 
 
 
  
Formulations 
Carr’s 
index 
(%) 
Critical 
orifice 
(mm) 
Angle of 
repose 
(degree) 
Flowability 
composite 
Index 
F0 (Heat treatment) 15.75 5 26.77 90.54 
F1 (Heat treatment) 14.78 5 26.48 91.38 
F2(Heat treatment) 17.74 5 27.56 88.69 
F0(Wet granulation) 18.61 4 26.48 89.94 
F1(Wet granulation) 13.54 4 26.01 93.63 
F2(Wet granulation) 12.88 4 26.19 93.95 
F0(Spray dried) 21.11 12 26.00 79.70 
F1(Spray dried) 23.42 12 27.70 77.04 
F2(Spray dried) 22.00 12 27.60 78.05 
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Figure 2-2. Compression profile of the co-processed excipients prepared by three 
different methods 
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Table 2-6. Specific surface area of the co-processed excipients prepared by three 
different methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Formulations Specific surface area (m2/g) 
F0 (Heat treatment) 2.0001±0.053 
F1 (Heat treatment) 0.2831±0.015 
F2 (Heat treatment) 0.1618±0.044 
F0 (Wet granulation) 2.3176±0.032 
F1(Wet granulation) 0.8545±0.009 
F2(Wet granulation) 0.5860±0.008 
F0(Spray dried) 7.7629±0.005 
F1(Spray dried) 3.5017±0.064 
F2(Spray dried) 2.7999±0.042 
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heat treated excipient. After addition of the plasticizer, the heat treated excipient showed 
less surface area than the wet granulated excipient for both formulations F1 and F2. This 
indicated the better interaction between the polymer and the plasticizer in wet granulation 
process. 
 
 
2.3.1.4.2 Heckel’s plot 
 
Heckel’s plot results (Figure 2-3) show that addition of plasticizer decreases the 
yield strength of the co-processed excipients for all preparation methods and the type of 
the plasticizer did not significantly affect the yield strength. This result suggests the 
plasticized excipients can deform easier than unplasticized excipient under compression 
force. All of the co-processed excipients formulations contain 70-80% DCP. DCP is a 
typical brittle material and will undergo fragmental deformation during compression. It 
doesn’t have the plastic properties and the slope of Heckel’s plot is close to zero. When 
DCP mixed with the plastic material CA, the mixture showed certain plastic properties, 
but the slope is still very small and requires more energy for deformation.  A plasticizer 
will add plasticity to the powder mixture and less energy is required for the plasticized 
mixture. In our study, we also found that preparation methods affect the yield strength. 
The order for the yield strength of the co-processed excipients is: spray dried< wet 
granulation< heat treatment. The possible explanation could be: a) the interaction 
between the plasticizer and CA: the spray dried method provides the best interaction and 
the least interaction during the heat treatment method; b) the surface area: the larger 
surface exposed to the compression force, the more area available for deformation and 
easier plastic deformation can be expected.  
 
 
2.3.2 Effect of formulation factors 
 
 
2.3.2.1 Physical characteristic 
 
The physical properties of the co-processed excipients prepared from different 
plasticizers and different concentrations of plasticizer were listed in Tables 2-7 and 2-8. 
All the formulations listed in Tables 2-7 and 2-8 exhibits very similar physical 
properties. This indicates the process method played a major role in controlling the 
physical properties of the co-processed excipients. The formulation factors have less 
influence on the physical properties of the final excipients.  
 
 
2.3.2.2 Flow characteristic 
 
Similar results were observed for flow characteristic as shown in Tables 2-9 and 
2-10. All of the formulations prepared by the spray dried method showed similar flow 
properties. The flow characteristic of the granules is directly related to the shape and size 
of the granules. Because all of the formulations showed the similar density, particle size 
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Figure 2-3. Heckel’s plot of the co-processed excipients prepared by three 
different methods 
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Table 2-7. Physical properties for the co-processed excipients prepared from 
different plasticizers by using spray dried method 
 
 
 
 
 
Table 2-8. Physical properties for the co-processed excipients prepared from 
different concentrations of plasticizer by using spray dried method 
 
 
 
 
 
  
Formulations 
Bulk 
density 
(g/ml) 
Tap 
density 
(g/ml) 
Carr’s 
index 
(%) 
Powder 
porosity 
(%) 
Geometric 
mean 
particle 
size ( µm) 
F0 (no plasticizer) 0.52 0.68 21.11 73.88 249.36 
F1(ATEC) 0.55 0.73 23.42 73.40 261.44 
F2(ATBC) 0.54 0.69 22.00 72.60 247.16 
F3(TEC) 0.54 0.67 18.35 71.32 267.94 
F4(DBS) 0.55 0.73 25.44 71.39 278.92 
Formulations 
Bulk 
density 
(g/ml) 
Tap 
density 
(g/ml) 
Carr’s 
index 
(%) 
Powder 
porosity 
(%) 
Geometric 
mean particle 
size ( µm) 
F0(no plasticizer) 0.52 0.68 21.11 73.88 249.36 
F5(2.5%ATBC) 0.52 0.67 22.16 74.07 257.36 
F6(5% ATBC) 0.53 0.66 18.97 73.35 247.50 
F2(10%ATBC) 0.54 0.69 22.00 72.60 247.16 
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Table 2-9. Flow properties for the co-processed excipient prepared by different 
plasticizers by using spray dried method 
 
 
 
 
 
Table 2-10. Flow properties for the co-processed excipient prepared by different 
concentrations of plasticizer by using spray dried method 
 
 
  
Formulations Carr’s index (%) 
Critical 
orifice(mm) 
Angle of repose 
(degree) 
Flowability
composite 
index 
F0(no plasticizer) 21.11 12 26.00 79.70 
F5(2.5%ATBC) 22.16 12 27.76 77.83
F6(5% ATBC) 18.97 12 27.07 80.42
F2(10%ATBC) 22.00 12 27.60 78.05 
Formulations Carr’s index (%) 
Critical 
orifice(mm) 
Angle of repose 
(degree) 
Flowability 
composite 
index 
F0 (no plasticizer) 21.11 12 26.00 79.70 
F1 (ATEC) 23.42 12 27.70 77.04 
F2 (ATBC) 22.00 12 27.60 78.05 
F3 (TEC) 18.35 14 30.48 76.34 
F4 (DBS) 25.44 14 27.36 73.69 
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distribution and particle shape, the similar flow properties can be expected. The 
flowability index for the formulations is greater than 70, which suggest the good 
flowability of the granules and suitable for direct compression. 
 
 
2.3.2.3 Compactability 
 
 
2.3.2.3.1 Compression profile 
 
The compression profile of the co-processed excipients was affected by the type 
of plasticizers and the concentrations of plasticizer as shown in Figures 2-4 and 2-5. The 
tensile strength was decreased after addition of different type of plasticizers. The tablets 
containing the most hydrophilic plasticizer TEC showed the highest tensile strength, the 
lowest tensile strength was observed for tablets containing plasticizer DBS. The reasons 
of the tensile strength difference caused by the type of plasticizer can be explained by the 
hydrophobicity of the plasticizer and the interaction of plasticizer with CA. Based on the 
Log P value, the hydrophobicity of plasticizers used in this study is:  
ATBC>DBS>ATEC>TEC. The hydrophobic plasticizer is prone to contribute to the 
hydrogen bonding between the solid particles, therefore better mechanical strength. For 
the plasticizers with similar hydrophobicity, the interaction of the plasticizer with CA 
played a role. The interaction of the plasticizer with CA can be assessed by the glass 
transition temperature of CA. The glass transition temperature result is shown in     
Figure 2-6. Four plasticizers used in this study all can decrease the glass transition 
temperature of CA. The most effective plasticizer is ATEC which showed lowest glass 
transition temperature. The order of glass transition temperature of the plasticized CA is 
ATEC < TEC < ATBC< DBS. For the least effective plasticizer DBS, there is little 
interaction with the polymer and phase separation will take place during compression. 
The extra liquid available between the solid particles will affect the formation of solid 
bonding. The significant decrease of the tensile strength was observed. 
 
The effect of plasticizer concentration on the compression profile was 
demonstrated in Figure 2-5. When the concentration of plasticizer is below 5%, addition 
of the plasticizer increases the tensile strength of the tablets. But when the concentration 
of plasticizer climbs to 10%, the presence of plasticizer decreases the mechanical strength 
of the tablets. The similar phenomenon was observed when compressing MCC with a 
small amount of water as plasticizer and compressing HPMC with a small amount of 
water as plasticizer [5, 80]. In their study [80], it was found that bonding area increased 
after adding the plasticizer. But upon increasing the plasticizer concentration, the bonding 
strength is much reduced due to the softening effect of the plasticizer on the polymer. 
This effect is stronger than the effect of increasing the bonding area. This explained the 
effect of plasticizer concentration on the tensile strength of tablets.  
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Figure 2-4. Compression profile of the co-processed excipients prepared from 
different plasticizers by using spray dried method 
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Figure 2-5. Compression profile of the co-processed excipients prepared from
different concentrations of plasticizer by using spray dried method 
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Figure 2-6.  Glass transition temperature of CA with different plasticizers 
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2.3.2.3.2 Heckel’s plot 
 
The effect of plasticizers on Heckel’s plot is demonstrated in Figure 2-7. All the 
plasticizers used in this study lower the yield strength. The type of plasticizer did not 
affect the yield strength of co-processed excipients, but the concentration of plasticizer 
affects the plasticity of the co-processed excipients. As shown in Figure 2-8, the yield 
strength of the co-processed excipient is decreased when increasing the plasticizer 
concentration. This suggests increased plasticity of the co-processed excipient with high 
concentration of plasticizer. 
 
 
2.4 Conclusions 
 
The co-processed excipients with CA, plasticizer and inert excipient were 
successfully prepared by using three different methods. The physical, flow and 
compaction properties of the co-processed excipients were influenced by the formulation 
factors as well as the process methods.   We found the physical and flow properties are 
controlled by the process methods and the formulation factors have less impact.  
 
The co-processed excipients prepared in this study all showed good flow 
characteristic. The flowability of heat treated and wet granulated co-processed excipients 
are better than the spray dried excipients. The compactability of the co-processed 
excipients is affected by both process methods and formulation factors. The spray dried 
process produced more porous particles with larger surface area. These particles required 
the least energy for plastic deformation during compression and formed the tablets with 
highest mechanical strength. The wet granulated excipients showed moderate plastic 
deformation capacity and resulting tablets with acceptable tensile strength. The heat 
treated excipients required more energy to deform under compression pressure than the 
other two methods. The resulting tablets have poor mechanical property.  
 
For all preparation methods, addition of 10% plasticizer increases the plasticity of 
the final excipient and decreases the tablet tensile strength.  The tablets containing 
hydrophilic plasticizer showed better tensile strength than the hydrophobic plasticizer. 
The increased interaction between the plasticizer and the polymer also results in tablets 
with better tensile strength. The concentration of plasticizer also affects the 
compactability of the co-processed excipient. The tensile strength of the tablets increased 
at low plasticizer concentration and the reverse effect was observed on higher plasticizer 
concentration. Based on results obtained from the study, both wet granulated and spray 
dried excipients showed desired flowability and acceptable compactability. All of them 
appear to be satisfactory excipient candidates for direct compression formulation, but the 
controlled release capacity of these excipients needs to be investigated. 
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Figure 2-7. Heckel’s plot of the co-processed excipients prepared from different 
plasticizers by using spray dried method 
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Chapter 3. Sustained Release Properties and Drug Release Mechanism Study of a 
Novel Co-processed Excipient 
 
 
3.1 Introduction 
 
The co-processed plasticized cellulose acetate with inert excipients was 
successfully developed by three different methods as described in chapter two. Those co-
processed excipients showed good flowability, acceptable compactability and suitability 
for direct compression. 
  
In this chapter, we investigated the sustained release properties of the novel co-
processed excipients and the factors which can affect the drug release from the matrix 
tablets. The drug release mechanism for the matrix tablets was also studied by using two 
empirical mathematic equations. A freely water soluble drug propranolol hydrochloride 
was selected as the model drug to study the drug release characteristics from the matrices. 
The sparingly water soluble drug theophylline and water insoluble drug flurbiprofen were 
used to evaluate the drug solubility effect on the dissolution profile. 
 
 
3.2 Materials and Methods 
 
 
3.2.1 Materials 
 
Cellulose acetate with 39.8% acetyl content and 38 cp viscosities (CA 398-10 NF, 
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate 
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate 
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Regular dicalcium 
phosphate dihydrate (DCP, Rhodia Inc., Blue Island, IL) and milled dicalcium phosphate 
dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler. Magnesium 
stearate (Mallinckrodt, Paris, KY) was used as a lubricant. Propranolol hydrochloride was 
used as water soluble model drug, Theophylline anhydrous (BASF, Ludwigshafen, 
Germany) was used as sparingly water soluble drug and flurbiprofen (Sun Pharma, 
Maharashtra, India) was used as a water insoluble drug. 
 
 
3.2.2 Methods 
 
 
3.2.2.1 Tablets preparation 
 
For comparison purpose, the tablets containing different concentrations of 
unprocessed CA were prepared by a direct compression method. The formulations are 
listed in Table 3-1. Tablets were compressed on a Carver Press (Carver Inc., Wabash, 
IN) by using 3/8 inch flat face punch at 1.5 metric ton compression force. The dwell time  
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Table 3-1.  Formulations of the tablets prepared from the unprocessed CA 
 
 
  
  
Ingredients  Percentage (%) A1 A2 A3 
Propranolol hydrochloride  20 20 20 
CA 398-10 NF  15 30 50 
Regular DCP 64.5 49.5 29.5 
Magnesium stearate 0.5 0.5 0.5 
Total  100 100 100 
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is 3 seconds and the target weight is 400mg. 
 
Tablets containing the co-processed excipient were also prepared by direct 
compression method. All the tablets prepared by the co-processed excipients share the 
same formula. All the tablets contain 20% drug, 79.5% co-processed excipient and 0.5%  
magnesium stearate. The ingredients were mixed by passing through a 20 mesh sieve 3 
times and then compressed into 400mg tablets at the same compression condition as the 
unprocessed CA tablets.  In order to investigate the compression force effect, two 
additional compression forces 0.5 m ton and 1.0m ton also applied. 
 
 
3.2.2.2 In vitro dissolution study 
 
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation, 
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch 
were tested. 900 ml of distilled water, pH 7.4 phosphate buffer and pH 7.2 phosphate 
buffer at 37 ± 0.5°C was used as the dissolution medium for evaluate the release of 
propranolol hydrochloride, theophylline and flurobiprofen respectively. The samples 
were taken at predetermined time points for 12 hours. The absorbance of the solution was 
measured at 289 nm, 274nm and 277nm respectively by a UV-spectrophotometer 
(Perkin-Elmer Corporation, Norwalk, CT). The drug concentration and the percentage of 
drug release were calculated by the software DissLab®.  
 
In order to determine the pH effect on dissolution profile, 900ml simulated gastric 
fluid (without enzymes) and simulated intestine fluid (without enzymes) were used as 
dissolution medium. The tablets prepared by mixing propranolol hydrochloride and spray 
dried co-processed excipient F2 for evaluation. The drug dissolution profile was 
compared by using f2 value as described in Equation 3-1. 
 
 f2=50×log{[1+(1+1/n)∑ (Rtt=1 -Tt)
2
]
-0.5
×100} (Eq. 3-1) 
 
where f2 is a similarity factor, n is the number of sample times, Rt is the average 
percentage of drug released at time t for the reference sample, Tt is the average 
percentage of drug released at time t for the test sample. According to FDA’s guidance 
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider 
as similar or equivalent. 
 
 
3.2.2.3 Tablet porosity measurement 
 
The true density (ρt) of the lubricated drug and co-processed excipients mixture 
were determined by a helium pycnometer (AccuPyc 1330, Micromeritics, Norcross, GA). 
The density of the tablet (ρa) was calculated from Equation 3-2. 
 
 ρa = π* r2* l (Eq. 3-2) 
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where r is the radial of the tablet and l is the thickness of the tablet.  
 
The porosities of the tablets (ε) were calculated from the tablet density (ρa) and 
true density (ρt) of the mixture using the following Equation 3-3: 
 
 ε = 100 (1- ρa/ρt) (Eq. 3-3) 
 
 
3.2.2.4 Tablet surface examination 
 
The surface of tablets was first coated by 10nm gold particles for improving the 
conductivity. The morphology of the tablets surface was examined by the FEI XL-30 
Scannig Electron Microscopy. (SEM, FEI, Hillsboro, OR)  
 
 
3.2.2.5 Initial water penetration study 
 
The initial water penetration study of the tablets was performed in a 0.1% 
methylene blue solution. Tablets was first dipped into this solution for 1 minute, then 
taken out, wiped the excess liquid and cut into half to observe the surface and the cross 
section under the Olympus MIC-D microscope. (Olympus, Center Valley, PA). 
 
 
3.2.2.6 Drug solubility measurement 
 
The excess amount of drug was put in the corresponding dissolution medium, 
then vortexed for 3 minutes. The mixture was shaken for 7 days at 37°C to reach 
equilibrium. The sample was taken and centrifuged at 10000 rpm for 10 minutes. The 
supernatant was filtered by a 0.45µm membrane filter. The filtrate was diluted by the 
dissolution medium and the concentration of the dilution was determined by UV-
Spectrophotometer (Perkin-Elmer Corporation, Norwalk, CT).  
 
 
3.2.2.7 Drug release mechanism study 
 
Drug-release mechanism was studied by fitting the dissolution data to two 
empirical mathematical equations including Higuchi equation and power law.  
 
The Higuchi equation was developed in 1961 [11, 36] to describe the drug release 
from the inert matrix tablets. The equation is as following: 
 
 Qt= ൤S
2Dε
τ ൫2C0-εCS൯CSt൨
1
2
=kt
1
2 (Eq. 3-4) 
 
where Qt is the cumulative amount of drug released over a surface unit in time t; S is the 
surface area of the tablet; D denotes the drug diffusion coefficient in the matrix phase; Cs 
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is the drug solubility in the matrix; C0 represents the drug concentration in the matrix; ε is 
the porosity; τ denotes the tortuosity of the matrix; and k is the dissolution rate constant. 
 
Based on this equation, drug release at any given time is proportional to the 
square root of the time. The release rate constant k can be calculated from the dissolution 
profile. Dε/τ (effective diffusion coefficient) also can be calculated from the constant k 
and known drug and tablet properties. 
 
The general equation of the power law [45] is Equation 3-5. 
 
 Mt/ M∞=k*tn (Eq. 3-5) 
 
where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of 
drug released at infinite time; k is release constant incorporating structural and geometric 
characteristics of the system, and n is the release exponent indicating the mechanism of 
drug release.  
 
The release exponent ‘n’ in the power law takes multiple values based on 
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release 
mechanism is Fickian  diffusion; if the n value >0.89, Case-II transport in which the 
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89,  the 
“anomalous transport” takes place where  both  of drug diffusion and swelling of the 
polymer are involved. 
 
Addition to model fit, the geometric dimension of the tablets prepared with drugs 
of different solubility was measured before and after the dissolution by using the caliper. 
 
 
3.3 Results and Discussion 
 
 
3.3.1 Dissolution profile of unprocessed CA 
 
The previous research on CA for matrix tablet polymer demonstrated that the CA 
matrices are sensitive to the solubility of the drug [61]. As a retarding agent, it not 
suitable for controlling the release for freely water soluble drug from the matrix tablet. 
Our study showed in Figure 3-1 has an agreement with results from the literature. When 
the concentration of CA is 15% and 30%, more than ninety percent drug released within 
1 hour. Even the concentration of CA reaches to 50%, eighty percent of drug released 
within 2.5 hours. Because of the low bulk density of CA (0.289g/ml), the mixtures with 
higher concentration of CA exceeded the volume limitation of the die.  Tablet with higher 
concentrations of CA was not prepared in this study. These results confirmed that the 
unprocessed CA could not be used to formulate the sustained release matrix tablets for 
freely water soluble drug at concentrations less than 50%. 
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Figure 3-1. Dissolution profile of the tablets containing unprocessed CA 
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3.3.2 The effect of preparation process of co-processed excipients on drug release 
 
 
3.3.2.1 Dissolution profile 
 
The dissolution profile (Figure 3-2) shows that drug release characteristic was 
directly related to the preparation process and formulation factors of the co-processed 
excipients. All the tablets prepared from the heat treatment co-processed excipient have a 
rapid dissolution rate. More than 90% drug was released in the first hour. The tablets 
prepared from the wet granulated co-processed excipients show slower drug release rate. 
The slowest drug release rate was obtained from the tablets prepared from spray dried co-
processed excipient. For the co-processed excipients prepared from wet granulation 
method and spray dried method, addition of the plasticizer significantly decreased the 
drug release rate and the hydrophobic plasticizer ATBC demonstrated slower release rate 
than the hydrophilic plasticizer ATEC. Since the spray dried excipients provided the 
slowest sustained release profile among these three methods, it was selected for further 
investigation. The difference in drug release profiles can be explained by tablet porosity, 
tablet surface morphology and initial water penetration rate as discussed below. 
 
 
3.3.2.2 Tablet porosity 
 
For a hydrophobic matrix tablet, irregular pores will be formed during 
compression due to the boundaries of the particles. For this system, drug release must be 
preceded by the drug dissolution in medium filled pores and by diffusion through 
medium filled channels. The size, structure and amount of the pores are very important 
for controlling the drug release [81]. 
 
The porosity of the tablets is listed in Table 3-2. For all the co-processed 
excipient, despite of the preparation method, addition of plasticizer significantly 
decreases the porosity of the tablets (p<0.05). Fewer diffusion channels will be presented 
due to the decreased porosity. Therefore, the slower drug release profile was observed for 
the plasticized matrices than the unplasticized matrices. But the type of the plasticizer and 
the excipient preparation methods did not significantly affect the porosity of the tablets 
(p>0.05). Even though there is a clear dissolution difference among the tablets with 
different co-processed excipients, we could attribute the difference in porosity of the 
tablets alone. This result suggests the overall porosity is not the only factor which has 
influence on the drug dissolution.  Other factors such as hydrophobicity, size and 
tortuosity are also expected to play an important role in controlling the drug release from 
the matrix system. 
 
 
3.3.2.3 Tablet surface morphology 
 
Figure 3-3 showed the surface morphology of the tablets prepared from co-
processed excipient formula F2 with 20% propranolol hydrochloride. The surface of the  
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Figure 3-2. Dissolution profile of tablets containing the co-processed excipients 
prepared from different process methods 
 57 
Table 3-2. Porosity of the tablets prepared by propranolol hydrochloride and 
different co-processed excipients 
 
 
  
Preparation of co-
processed excipients 
Porosity (%) 
F0  F1  F2  
Heat treatment  17.06±1.00  10.12±1.60  10.77±0.54  
Wet granulation  17.30±1.34  10.68±0.72  10.92±1.25  
Spray drying  16.95±1.48  9.37±0.65  9.53±0.85  
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A: Tablet containing 20% propranolol and 79.5% heat treated excipient F2; B: tablet 
containing 20% propranolol and 79.5% wet granulated excipient F2; C: tablet containing 
20% propranolol and 79.5% spray dried excipient F2.  
Figure 3-3. SEM of tablet surface 
A 
B 
C 
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tablets prepared from the heat treatment excipient showed several big cracks, these cracks 
can act as channels for water penetration and drug diffusion, therefore resulting faster 
drug release. Small cracks were observed on the surface of the tablet prepared from the 
wet granulated excipient. A smooth and film-like surface was observed from the tablet 
prepared from the spray dried excipient. The small and individual pores were presented 
uniformly in the entire surface. This uniform structure can effectively reduce the water 
penetration and result in a prolonged drug release. These observations reveal the surface 
characteristics and the effect of pore structure on water penetration and can be used for 
explaining the dissolution differences among the preparation methods of co-processed 
excipients. This finding is in good agreement with the literature [61]. 
 
 
3.3.2.4 Initial water penetration study 
 
Initial water penetration results are shown in Figure 3-4. The rapid initial water 
penetration rate was found in the tablet prepared from the heat treatment excipient. Water 
penetrates the whole body of the tablet within 1 minute. For the wet granulated excipient, 
the surface of tablet showed a broken film structure, water penetrated through the broken 
parts of the film. The water penetrated to 1/3 of the tablet within 1 minute. The slowest 
initial water penetration rate was obtained from the tablet prepared by spray dried co-
processed excipient. Water stayed primarily on the surface of the tablet and the body of 
the tablet appeared dry. This confirmed the finding from the tablet surface morphology 
study. The film-like surface structure prevents the water penetration thereby decreasing 
the drug release rate. 
 
 
3.3.3 The effect of co-processed excipients’ formulation on drug release 
 
 
3.3.3.1 The effect of the type of plasticizer 
  
The drug release rate was decreased while increasing the logP value of plasticizer 
as illustrated on Figure 3-5.  Since the similar porosity results was obtained for the 
tablets prepared by different plasticizers as shown in Table 3-3. The hydrophobicity of 
plasticizer plays a role for controlling the drug release. For hydrophilic plasticizers TEC 
and ATEC, they have some solubility in the water. They will dissolve in the water while 
in contact with the aqueous dissolution medium and leave the pores for water penetration 
and drug diffusion resulting in a rapid dissolution rate. DBS and ATBC are hydrophobic 
and practically insoluble in the water. The rate of these two hydrophobic plasticizers 
leaving the matrices is much slower than those two hydrophilic plasticizers. According to 
the glass transition temperature of CA with different plasticizers (Figure 2-4), ATBC has 
the better interaction with the CA compare to DBS. Therefore, ATBC remains in the 
matrices longer than DBS. Thus the slowest drug release rate was observed for the tablets 
containing ATBC as a plasticizer. 
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A: Surface of tablet containing 20% propranolol and 79.5% heat treated excipient F2; B: 
cross-section of tablet containing 20% propranolol and 79.5% heat treated excipient F2; 
C: surface of tablet containing 20% propranolol and 79.5% wet granulated excipient F2; 
D:tablets containing 20% propranolol and 79.5% spray dried excipient F2. 
Figure 3-4. Initial water penetration study 
A B 
C D 
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Figure 3-5. The effect of the type of plasticizer of co-processed excipient on the 
drug release 
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Table 3-3. Porosity of tablets prepared by propranolol hydrochloride and co-
processed excipients with different plasticizers 
 
 
 
 
 
 
 
 
  
Formulations Porosity (%) 
F0(no plasticizer) 16.95±1.48 
F1(ATEC) 9.37±0.65 
F2(ATBC) 9.53±0.85 
F3(TEC) 10.05±0.88 
F4(DBS) 10.66±1.76 
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3.3.3.2 The effect of plasticizer concentration  
 
Figure 3-6 demonstrates the concentration of plasticizer has a strong impact on 
the drug release rate. The drug dissolution rate was decreased with increasing 
hydrophobic plasticizer concentration. According to the Heckel’s plot result (Figure 2-7), 
the plasticity of the granules was also increased with increasing concentration of 
plasticizer. Granules with better plasticity form more solid bonding during compression 
and lead to harder tablet at the same compression pressures. Therefore significant 
reduction of tablet porosity (p<0.05) was observed as shown in Table 3-4, also showing a 
difference in drug dissolution profile. 
 
 
3.3.4 The effect of compression force on drug dissolution 
 
One common feature of the hydrophobic matrix tablet is the compression force 
effect on drug dissolution. Tablets compressed at high compression force result in less 
volume and lower porosity. As a consequence, the drug release rate will be slower at the 
higher compression force. This phenomenon was observed in different hydrophobic 
matrix systems. In our study, the compression force effect on drug dissolution profile was 
investigated on the tablets containing 20% drug propranolol hydrochloride and spray 
dried co-processed excipient F2. The result is shown in Figure 3-7. It is evident that drug 
release rate decreased as compression force increased. The porosity of the tablets as 
shown in Table 3-5 confirmed the porosity decreased as the compression force increased. 
These results show typical hydrophobic matrix tablet behavior when using this novel co-
processed excipient as a retarding agent. 
 
 
3.3.5 pH effect of dissolution medium on drug dissolution profile 
 
In our study, CA is a pH-independent polymer. It remains insoluble in GI tract 
(pH 1.2-7.4). The model drug propranolol hydrochloride is a hydrochloride salt with pka 
9.5. When the pH ranges from 1.2 to 7.4, it shows a pH independent solubility profile. 
The result of pH effect on drug dissolution was shown in Figure 3-8. The drug release 
rate in three different medium are very close to each other.  We used the dissolution 
profile of water as reference, the f2 value of the simulated gastric fluid (SGF) is 71.2 and 
the simulated intestinal fluid (SIF) is 95.7. The f2 results suggest the three dissolution 
profiles are similar. Based on this result, we can conclude this novel co-processed 
excipient can provide a pH independent dissolution profile for a pH insensitive drug. 
However, for a pH sensitive drug, the dissolution profile is expected to vary under 
different pH conditions as the solubility of the drug changes. 
 
 
3.3.6 Drug solubility effect on drug dissolution profile 
 
Three drugs with different water solubility were selected in this study. The drug 
solubility in respect to the dissolution medium were tested and listed in Table 3-6. Based  
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Figure 3-6. The effect of plasticizer concentration of co-processed excipient on the 
drug release 
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Table 3-4. Porosity of tablets prepared by propranolol and co-processed 
excipients with different concentration of ATBC 
 
 
 
 
 
 
 
  
Formulations Porosity (%)
F0(no plasticizer) 16.95±1.48 
F5(2.5%ATBC) 15.63±1.06 
F6(5% ATBC) 12.35±0.84 
F2(10%ATBC) 9.53±0.85 
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Figure 3-7. Compression force effect on drug release 
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Table 3-5. Porosity of tablets prepared by propranolol and spray dried excipient 
F2 at different compression force 
 
 
 
 
 
 
  
Compression force Porosity (%) 
0.5 m ton 14.63±1.26 
1.0 m ton 10.97±0.63 
1.5 m ton 9.53±0.85 
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Figure 3-8. pH effect on drug release profile 
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Table 3-6. Solubility of different drugs in dissolution medium at 37°C 
 
 
 
  
Drug Dissolution medium Solubility (mg/ml) 
Propranolol hydrochloride DI water 192.79±1.93 
Theophylline anhydrous pH 7.4 phosphate buffer 11.19±0.18 
Flurbiprofen pH 7.2 phosphate buffer 4.52±0.07 
 70 
on the solubility result, propranolol hydrochloride was used as a freely water soluble 
drug; theophylline anhydrous was used as sparingly soluble drug and flurbiprofen was 
used as water insoluble drug. The solubility effect on drug dissolution profile was 
illustrated in Figure 3-9. For all the co-processed excipients selected in this study, the 
drug with higher solubility always show faster release rate. For the same drug, the order 
of the release rate is F0> F1> F2.  This order is valid for all three drugs. This result 
indicates the plasticized co-processed excipient has better control release ability than the 
unplasticized co-processed excipient. However, the difference of the drug release rate 
between the plasticized excipient and unplasticized excipient for three drugs is not the 
same. The freely soluble drug propranolol hydrochloride exhibits a large difference (more 
than 40% release difference in 12hours) in dissolution profile between the plasticized 
formulation and unplasticized formulation. While there is a small amount decrease (less 
than 10% release difference in 12hours) of plasticized formulation for the water insoluble  
drug flurbiprofen was observed. This result suggests the plasticizer effect has more 
impact when utilized on a water soluble drug. 
 
 
3.3.7 Drug release mechanism study 
 
 
3.3.7.1 Higuchi model 
 
The Higuchi model was used to plot the drug release profile of the tablets with 
three different drugs and two different spray dried co-processed excipients. The results 
were displayed in Figures 3-10 and 3-11. All six formulations showed a good fit (R2 
>0.98) for the Higuchi model. This indicates the drug release from the novel co-
processed excipient matrix follows square root kinetics. The constant K which is the 
slope in the Higuchi equation represents the drug release rate. A higher K value was 
observed for unplasticized matrices (F0) in spite of the solubility of the drug. The drug 
with higher solubility also showed a higher K value for both plasticized and unplasticized 
matrices. 
 
Typically, two factors are responsible for reducing the drug diffusion coefficient 
in the matrix. One is the porosity factor ε. Since the drug cannot cross the solid matrix, 
the void space available for drug diffusion is reduced by 1/ε.  Another is tortuosity factor 
τ. The pores structure in the matrix does not tend to be straight and the drug need to travel 
longer distance in order to diffuse. The diffusion coefficient is reduced by the increasing 
path length which is a tortuosity factor τ. The effective diffusion coefficient from the 
matrix considered both factors and is defined as:  
 
 Deff = Dε/τ (Eq. 3-6) 
 
where Deff is the effective diffusion coefficient; D is diffusion coefficient. According the 
Higuchi equation, after we know the K, Cs, C0 and ε, Deff can be calculated. Deff describes 
the real situation for drug diffusion from the matrix [82].  
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The Deff for six different matrices was calculated and listed in Table 3-7. For all 
three drugs, the Deff in an unplasticized matrix (F0) is higher than in a plasticized matrix 
(F2). This indicates the presence of the plasticizer can help to prevent the drug diffusion 
from the matrix.  
 
 
3.3.7.2 Power law model 
 
The same six dissolution profiles were fitted to the logarithmic transformed power 
law equation. The results were illustrated in Figures 3-12 and 3-13. The n value which is 
the slope of logarithm transformed power law equation indicates the drug release 
mechanism. For all the tablets prepared by the spray dried co-processed excipients F2, n 
values for all drugs are less or close to 0.45. This suggests drug release is controlled by 
Fickian diffusion. For the tablets prepared by the spray dried co-processed excipient F0, n 
values for water insoluble drug flurbiprofen and sparingly water soluble drug 
theophylline are less or close to 0.45. But n value for water soluble drug propranolol 
hydrochloride is 0.621, which suggests both drug diffusion and matrix relaxation take 
place.  
 
For the hydrophobic matrix tablet, the tablet will remain intact after dissolution. 
Since the polymer CA is water insoluble and does not hydrate in the water, the size 
change of matrix tablet during dissolution was not expected. Table 3-8 listed the tablet 
size change after the dissolution. Except for the tablet containing propranolol 
hydrochloride and spray dried F0, other tablets all maintained the similar size after 
dissolution. This confirmed with the result of the power law equation that tablet 
relaxation did not contribute significantly to the drug release. For the tablet comprising 
freely water soluble drug and unplasticized excipient, a 13.35% increase in thickness was 
observed. The picture taken after dissolution (Figure 3-14B) showed the several cracks 
in the body of tablet. This cracks can shorten the drug diffusion pathway, therefore 
increase the drug release rate. These cracks also contribute to the matrix relaxation 
mechanism. Because we did not observe the matrix relaxation in other 5 formulations, it 
can be concluded this is not caused by the polymer relaxation. The possible reason maybe 
the high osmotic pressure generated by the freely water soluble drug propranolol 
hydrochloride affected the tablet structure and caused the resulting cracks. However for 
the tablet prepared with propranolol hydrochloride and plasticized co-processed excipient 
F2 the plasticized tablet is more robust and can withstand the osmotic pressure and the 
tablet structure can be maintained. For the water soluble drug, the plasticizer can 
maintain tablet shape during dissolution, therefore prolonging the drug release. 
 
 
3.4 Conclusions 
 
The spray dried co-processed excipients successfully controlled the release of a 
freely water soluble drug from a matrix tablet. It demonstrated a slower drug release 
profile than the co-excipients prepared by the other two processing methods. The surface 
morphology and initial water penetration study found the spray dried co-processed 
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Table 3-7. Higuchi release constant and effective diffusion coefficient for 
different drugs in different matrices 
 
 
 
 
 
 
 
 
 
  
Formulations K value Deff 
Propranolol (F0) 13.47 0.00739 
Theophylline (F0) 5.0973 0.014697 
Flurbiprofen (F0) 3.4642 0.016688 
Propranolol (F2) 5.4992 0.001108 
Theophylline (F2) 3.3455 0.006296 
Flurbiprofen (F2) 2.7234 0.010293 
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Figure 3-12. Power law model fitting for tablets prepared from the co-processed 
excipient F0 
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Table 3-8. Tablet size change after dissolution 
 
 
 
 
 
 
 
 
 
  
Formulations Diameter change (%) Thickness change(%) 
Propranolol (F0) 2.65±0.3 13.35±0.43 
Theophylline (F0) 1.57±1.31 0.66±0.01 
Flurbiprofen (F0) 2.09±1.23 0.29±0.21 
Propranolol (F2) 0.18±0.32 0.28±0.57 
Theophylline (F2) 0.10±0.10 0.66±0.16 
Flurbiprofen (F2) 0.76±0.26 0.19±0.42 
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A: Before dissolution; B: after 12hours dissolution. 
 
 
 
 
 
Figure 3-14. Pictures of tablet containing 20% propranolol hydrochloride and
spray dried excipient F0  
B 
A 
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excipient can form the continuous film liked structure on the tablet surface which can 
effectively prevent water penetration and drug diffusion. The drug release rate from the 
matrix tablets containing the novel spray dried excipients can be decreased by increasing 
the hydrophobicity of the plasticizer and plasticizer concentration. The drug release rate 
from the matrix was affected by the compression force but not the pH of the dissolution 
medium. The drug release from the matrix tablet can be described by Higuchi equation 
and the power law equation. Based on porosity results and drug release mechanism study, 
addition of plasticizer to the co-processed excipients showed decrease in the drug release 
rate is due to three reasons: a) decrease in the porosity of the tablet; b) decrease in the 
effective diffusion coefficient; c) assist in maintaining tablet structure during dissolution. 
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Chapter 4. Hydrophilic Polymer Effect on the Plasticized Cellulose Acetate Matrix 
Tablets 
 
 
4.1 Introduction 
 
For a highly water soluble drug, the use of hydrophilic polymer alone for 
controlling the drug release from the matrix is restricted due to the rapid diffusion 
through the gel layer. For such drugs, hydrophobic polymers are suitable as retarding 
agents. The hydrophobic polymers can offer several advantages including good stability 
at varying pH and resistant to the environmental moisture [2, 17, 19] However, for a 
simple monolithic hydrophobic matrix, an increase of the diffusion pathway and a 
decrease of the effective diffusion area as a function of time often results in incomplete 
release within the gastrointestinal transit time. To modulate drug release, it may be 
necessary to incorporate soluble ingredients such as lactose or PEG into formulation. The 
presence of soluble ingredient in the formulations helps to form numerous pores in 
hydrophobic matrix network for water penetration and drug diffusion. Therefore, 
complete drug release can be obtained from the highly porous matrix [44]. But burst 
release is a potential risk when an excessive amount of water soluble ingredient is present 
in the hydrophobic matrix. The hydrophilic nature of these pore formers can result the 
rapid surface erosion and cause fast surface drug release initially. 
 
In this chapter, we developed a swellable porous matrix tablet by incorporating a 
small amount of hydrophilic polymer into the hydrophobic matrix. The swelling property 
of the hydrophilic polymer during dissolution is utilized to generate highly porous 
structure in the hydrophobic matrix for obtaining complete drug release. The initial 
viscous gel formation of the hydrophilic polymer upon contacting with water also can 
help to suppress the burst release of the drug.  The effect of the type of hydrophilic 
polymer, the concentration of hydrophilic polymer, the viscosity of hydrophilic polymer 
and the particle size of hydrophilic polymer on drug release and the drug release 
mechanism from this novel system was investigated in this chapter.  
 
 
4.2 Materials and Methods 
 
 
4.2.1 Materials 
 
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF, 
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate 
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate 
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Milled dicalcium 
phosphate dihydrate (milled DCP Innophos Inc., Cranbury, IL) was used as filler. 
Magnesium stearate (Mallinckrodt, Paris, KY) was used as a lubricant. Spray dried 
lactose monohydrate (Lactose 316, Foremost, Baraboo, WI) and partially pregelatinized 
corn starch (Starch® 1500, Colorcon, West point, PA) were used as pore former for 
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hydrophobic matrix tablet.  Propranolol hydrochloride was used as a water soluble model 
drug. Five different viscosity grades (E5, E50, K100 CR, K4M CR and K100M CR) of 
hydroxypropyl methylcellulose (HPMC, Dow Chemical Company, Midland MI), the 
highest viscosity grade of hydroxypropyl cellulose (HPC HXF, Asland, Covington, KY), 
hydroxyethyl cellulose (HEC HHX, Asland, Covington, KY) and polyethylene oxide 
(Polyox® 303, Dow Chemical, Midland MI) were selected as hydrophilic polymer. 
Methylene blue (JT Baker, Phillipsburg, NJ) and FD&C orange (Opatint PG, Colorcon, 
West point, PA) were used as dye to indicate the different components in the tablets.   
 
 
4.2.2 Methods 
 
 
4.2.2.1 Tablets preparation 
 
The tablet formulations were listed in Tables 4-1 to 4-6. The tablets were 
prepared by direct compression method. All the ingredients were mixed by passing 
through 20 mesh sieve 3 times. The mixtures were compressed on a Carver Press (Carver 
Inc., Wabash, IN) by 3/8 inch flat face punch at 1.5 metric ton compression force. The 
dwell time is 3 seconds and the target weight is 400mg.  
 
 
4.2.2.2 In vitro dissolution study 
 
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation, 
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch 
were tested. 900 ml of distilled water at 37 ± 0.5°C was used as the dissolution medium 
for evaluate the release of propranolol hydrochloride. The samples were taken at 
predetermined time points for 12 hours. The absorbance of the solution was measured at 
289 nm by a UV-spectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug 
concentration and the percentage of drug release were calculated by the software 
DissLab®.  
 
The difference of drug dissolution profiles was evaluated by using f2 value as 
described in Equation 4-1 [24]. 
 
 f2=50×log{[1+(1+1/n)∑ (Rtt=1 -Tt)
2
]
-0.5
×100} (Eq. 4-1) 
 
where f2 is a similarity factor, n is the number of sample times, Rt is the average 
percentage of drug released at time t for the reference sample, Tt is the average 
percentage of drug released at time t for the test sample. According to FDA’s guidance 
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider 
as similar or equivalent. 
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Table 4-1. Formulations for tablets prepared with different type of pore formers 
 
Ingredients  Percentage (%) H0 H2 P1 P2 
Propranolol hydrochloride 20 20 20 20 
Spray dried excipient F2 79.5 74.5 74.5 74.5 
Polyox® 303 0 5 0 0 
Lactose 316 0 0 5 0 
Starch® 1500 0 0 0 5 
Magnesium Stearate 0.5 0.5 0.5 0.5 
Total  100 100 100 100 
 
 
 
 
Table 4-2. Formulations for tablets prepared with different concentrations of 
hydrophilic polymer 
 
 
 
 
  
Ingredients  Percentage (%) H0 H1 H2 H3 
Propranolol hydrochloride 20 20 20 20 
Spray dried excipient F2 79.5 77 74.5 69.5 
Polyox®  303 0 2.5 5 10 
Magnesium Stearate 0.5 0.5 0.5 0.5 
Total  100 100 100 100 
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Table 4-3. Formulations for tablets prepared with different hydrophilic polymers 
 
Ingredients  Percentage (%) H2 H4 H5 H6 
Propranolol hydrochloride 20 20 20 20 
Spray dried excipient F2 74.5 74.5 74.5 74.5 
Polyox®  303 5 0 0 0 
HPMC K100M CR 0 5 0 0 
HPC HXF  0 0 5 0 
HEC HHX 0 0 0 5 
Magnesium Stearate 0.5 0.5 0.5 0.5 
Total  100 100 100 100 
 
 
 
 
Table 4-4. Formulations for tablets prepared with different viscosity grades of 
hydrophilic polymer 
 
 
 
 
  
Ingredients Percentage (%) H7 H8 H9 H10 H4 
Propranolol hydrochloride 20 20 20 20 20 
Spray dried excipient F2 74.5 74.5 74.5 74.5 74.5 
HPMC E5 5 0 0 0 0 
HPMC E50 0 5 0 0 0 
HPMC K100LV  0 0 5 0 0 
HPMC K4M 0 0 0 5 0 
HPMC K100M 0 0 0 0 5 
Magnesium Stearate 0.5 0.5 0.5 0.5 0.5 
Total  100 100 100 100 100 
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Table 4-5. Formulations for tablets prepared with different co-processed 
excipients and hydrophilic polymer Polyox 303 
 
 
 
 
 
Table 4-6. Formulations for tablets prepared with different co-processed 
excipients and hydrophilic polymer Polyox 303 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ingredients  Percentage (%) H2A H2B H2C 
Propranolol hydrochloride 20 20 20 
Spray dried excipient F2 74.5 74.5 74.5 
Polyox® 303 (20-60mesh) 5 0 0 
Polyox® 303 (60-140mesh) 0 5 0 
Polyox® 303 (<140mesh) 0 0 5 
Magnesium Stearate 0.5 0.5 0.5 
Total  100 100 100 
Ingredients  Percentage (%) H11 H12 H2 
Propranolol hydrochloride 20 20 20 
Spray dried excipient F0 74.5 0 0 
Spray dried excipient F1 0 74.5 0 
Spray dried excipient F2 0 0 74.5 
Polyox® 303  5 5 5 
Magnesium Stearate 0.5 0.5 0.5 
Total  100 100 100 
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4.2.2.3 Optical microscopic examination 
 
In order to identify different components of tablet during dissolution, the colored 
tablets were prepared. An appropriate amount of methylene blue was added to the co-
processed excipient formulation in 0.1% concentration.  The methylene blue was 
processed along with the other excipient as the same condition. The final co-processed 
excipient appeared a dark blue color. An appropriate amount of FD&C orange dye was 
dispersed in the isopropanol alcohol, and then mixed with Polyox® 303. The wet mass 
was kept in 40°C oven overnight to remove the solvent. The dried particles were passed 
through 20 mesh sieve to obtain orange color Polyox® 303. The colored tablets were 
prepared by blue co-processed excipient F2, orange Polyox® 303, white model drug 
propranolol hydrochloride and lubricant as the same concentration and same preparation 
procedure as the formulation H0 and H2. These colored tablets were placed in the same 
dissolution condition as the normal tablets for 1, 6 and 12 hours, and then took it out to 
observe the surface and cross-section under the Olympus MIC-D microscope. (Olympus, 
Center Valley, PA). The geometric dimension of the tablets was measured by using the 
caliper. 
 
 
4.2.2.4 Mathematic model fitting 
 
 
4.2.2.4.1 Power law equation 
 
Drug-release mechanism was first studied by fitting the dissolution data to the 
power law equation [45]. 
 
 Mt/ M∞=k*tn (Eq. 4-2) 
 
where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of 
drug released at infinite time; k is release constant incorporating structural and geometric 
characteristics of the system, and n is the release exponent indicating the mechanism of 
drug release.  
 
The release exponent ‘n’ in the power law takes multiple values based on 
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release 
mechanism is Fickian  diffusion; if the n value >0.89, Case-II transport in which the 
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89,  the 
“anomalous transport” takes place where  both  of drug diffusion and swelling of the 
polymer are involved. 
 
 
4.2.2.4.2 Peppas and Shalin equation 
 
Peppas and Shalin equation [50] is a modification of power law equation. It was 
performed by decoupling diffusion and “Case-II transport” with the following expression: 
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 Mt/ M∞=k1*tm + k2*t2m (Eq. 4-3) 
 
where k1 and k2 are the release constants and m is the pure Fickian diffusion exponent.  
The exponent m is related to the aspect ratio of the tablets. . For the aspect ratio of tablet 
around 3, the m value is 0.45. And m=0.45 was used in our study. The first term in the 
right hand of the Equation 4-3 represents the contribution of Fickian diffusion (F) and 
the second term represents the contribution of tablet structure relaxation (R). R/F ratio 
can be calculated using Equation 4-4: 
 
 R/F = k2*tm/k1 (Eq. 4-4) 
 
The dominant drug release mechanism can be determined by the R/F ratio at any 
given time during dissolution. The model fit was performed by the software GraphPad 
Prism 4. 
 
 
4.3 Results and Discussion 
 
 
4.3.1 The effect of different pore formers on drug dissolution 
 
Incompletely release is a common problem associated with the hydrophobic 
matrix tablet. The typical solution is to add water soluble pore formers such as lactose 
and PEG to the matrix. The water soluble ingredient in the matrix will dissolve during 
dissolution and the pores will be formed in the matrix after the soluble material leached 
out. Those pores can act as the channels for water penetration and drug diffusion, 
therefore help to increase the drug release at the final stage. In our study, we selected 
three different pore formers. There are lactose, Starch 1500 and Polyox® 303. Lactose is 
a traditional pore former and easily dissolves in the water. Starch 1500 is a partially 
gelatinized starch and it is not soluble in the water. But it will expand after absorbing the 
dissolution medium thus pores or cracks will be created in tablet structure. Polyox® 303 
is a water soluble polymer. It has swelling property and can form a viscous gel upon 
contact with dissolution medium. The gel will be eroded during dissolution and leave 
empty space in the matrix for drug diffusion. The effect of the three pore formers on the 
drug release was shown in Figure 4-1. Compared to the formulation without any pore 
former (H0), all the pore formers used in our study significantly increased the drug 
release at 12 hours (P<0.05). Due to the swelling property of Starch® 1500 and Polyox® 
303, the swollen tablets with large amount of water filled pores and cracks were observed 
after dissolution for both  formulations P2 and H2.The complete drug release (>90%) at 
12 hours was also observed for those two formulations. For formulation P1 which 
contains lactose as pore former, the external tablet size remained the same as original 
during dissolution. The drug release at 12 hours for P1 was only 78.59±0.40%. This 
indicates the pores generated inside are not sufficient for complete drug release. The 
impact of the pore formers on drug release was exhibited not only on the final stage but 
also on the initial stage.  A significant burst release at the first hour was observed for both  
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Figure 4-1. The effect of the pore formers on drug dissolution 
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formulation P1 and P2. This can be explained by the hydrophilic nature of lactose and 
Starch 1500. They can facilitate the surface erosion of the tablet resulting rapid surface 
drug release. Formulation H2 which contains Polyox® 303 as the pore former showed 
limited burst release at first hour. The first hour release of formulation H2 is similar as 
the formulation H0 without any pore former. Even though Polyox® 303 also has a 
hydrophilic nature, the initial viscous gel formation helped to prevent the rapid burst 
release. The viscous gel formation counterbalanced the hydrophilic nature of Polyox® 
303 Therefore a similar release rate during the first hour for formulation H0 and H2 was 
observed. 
 
 
4.3.2 The effect of the concentration of hydrophilic polymer on drug dissolution 
 
The concentration effect of the hydrophilic polymer was illustrated in Figure 4-2. 
Compared to the formulation without any hydrophilic polymer, addition of the 
hydrophilic polymer significantly increased the drug release at 12 hours (P<0.05). The 
addition of hydrophilic polymer has less influence on the initial drug release. The 
decreased drug release rate only took place on 0.25 hour while 0.5 hour and 1.0 hour 
remained similar (P>0.05). When the concentration of the hydrophilic polymer is in the 
range of 0-5%, the drug release rate increased with increasing hydrophilic polymer 
concentration. Once the concentration of hydrophilic reached 5%, further increasing the 
concentration of hydrophilic polymer to 10% did not change the drug release rate. This 
indicates the limit amount of the hydrophilic polymer that is required for improving the 
final drug release and an excess amount of hydrophilic polymer will not further 
contribute to modulating the drug release profile within these ranges. 
 
 
4.3.3 The type of hydrophilic polymer effect on drug dissolution 
 
Cellulose derivatives are most commonly used hydrophilic polymers in 
development of hydrophilic matrix tablets. To exclude the pH effect of the system, we 
selected three pH independent cellulose derivatives with similar viscosity but different 
substitution. These were HEC HHX, HPMC 100KM CR and HPC HXF. According to 
the chemical structure difference, the rank of hydrophilicity is HEC> HPMC> HPC. Due 
to the difference of the hydrophilicity, these polymers have different erosion and swelling 
behavior. It was demonstrated that those polymers exhibited different sustained release 
behavior as the hydrophilic matrix tablets were developed. In addition to the cellulose 
derivatives, another commonly used pH independent hydrophilic polymer polyethylene 
oxide (Polyox® 303) was chosen. It is a hydrophilic polymer with relatively fast swelling 
and erosion rate. The type of hydrophilic polymer effect on the drug release was shown in 
Figure 4-3. Only formulation H5 prepared with the most hydrophobic polymer HPC 
showed slightly slower drug release at the final stage. The other dissolution curves are 
very close to each other. The f2 value was used for comparison of these four dissolution 
profiles. We selected formulation H2 as reference, the f2 values for H4, H5 and H6 are 
64.09, 69.65 and 74.99 respectively. This result suggests the type of hydrophilic polymer 
has less impact on the drug release in this matrix system. 
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4.3.4 The effect of hydrophilic polymer viscosity grades on drug dissolution 
 
The viscosity grade of hydrophilic polymer is a major factor on controlling the 
drug release from the hydrophilic matrix system. In order to discover the effect of 
viscosity of hydrophilic polymer on drug release from the plastic inert matrix system, five 
different viscosity grades of HPMC were selected. The five grades of HPMC included 
two low viscosity grades E5 and E50, one middle viscosity grade 100 LV, two high 
viscosity grades K4M and K100M. For the hydrophilic polymer with low viscosity, it 
could not be used alone for prepare the hydrophilic matrix tablets due to the less strength 
of gel layer and rapid erosion of tablets [2]. The result of polymer viscosity effect was 
demonstrated in Figure 4-4. Initially, the drug release rate slightly decreased with an 
increase in viscosity of hydrophilic polymer. The drug release decrease at the first hour is 
not statistically significant between formulations containing E5 and E50 (P>0.05), but 
statistically significant between formulations containing E5 and K100, K4M or K100M 
(P<0.05). There is no statistical difference on drug release at the first hour among the 
formulations containing K100 LV, K4M and K100M. At the final stage, the viscosity of 
the polymer effect is opposite to the initial stage. Drug release increased as an increase in 
the viscosity of the hydrophilic polymer. The significant drug release increase (P<0.05) at 
12 hours was observed while increase the polymer viscosity from E5 to K100 LV. 
Further increase the polymer viscosity from K100 LV to K100M, the increase in drug 
release at 12 hours was not significant (P>0.05). This result can be explained by the 
insufficient swellability and less gel strength of the low viscosity grades of HPMC. Low 
viscosity grades HPMC formed weak gel layer initially then result rapid surface release 
and. insufficient swellability of low viscosity grades HPMC could not generate large size 
of pores for water penetration and drug diffusion then result incomplete release finally. 
From Figure 4-4, we also found that the middle to high viscosity grades polymer behave 
similar in terms of modulating the drug release from the plastic matrix system.  We took 
formulation prepared with K100 M as a reference, f2 values for formulations prepared 
with K4M and K100 are 79.78 and 86.43 respectively. This may be due to two reasons: 
1) the swellability of the hydrophilic polymer with higher viscosity was restricted by the 
hydrophobic matrix network; 2) the fast erosion rate of the middle viscosity grade 
hydrophilic polymer result drug leaches out from the matrix. 
 
 
4.3.5 The particle size of hydrophilic polymer effect on drug dissolution 
 
The particle size of the hydrophilic polymer is another factor which affects the 
drug release from the hydrophilic matrix system. The hydrophilic polymer with large 
particle size often exhibits slower hydration rate and result fast drug release. Three 
fractions of Polyox® 303 were selected to study the particle size effect on the drug 
release from this matrix system. The result was shown in Figure 4-5. Three dissolution 
profiles are almost overlapped in this picture. This suggests the particle size of this 
hydrophilic polymer did not affect the drug release from this matrix system. This also 
indicates the drug release was not sensitive to the hydration rate of the hydrophilic 
polymer. 
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4.3.6 The effect of formulation factors of co-processed excipient on drug dissolution 
 
Three different co-processed excipients prepared by spray dried method were 
selected. The hydrophilic polymer Polyox® 303 was fixed at 5% for all formulations in 
the matrix. Figure 4-6 showed the effect of the co-processed excipient on drug 
dissolution.  The tablets prepared by the unplasticized co-processed excipient F0 showed 
rapid drug release, more than 80% drug released at 6 hours. These tablets could not 
maintain their shape during the dissolution. All the tablets fall apart after dissolution.  
The unplasticized matrix could not withstand the stretch of the tablet. The rigid and 
brittle bond was broken by the swell of the hydrophilic polymer. On the contrast, the 
plasticized matrix tablets H2 (ATBC as plasticizer) and H12 (ATEC as plasticizer) all 
swollen but still kept intact at the end of dissolution. This can be explained by the 
plasticizer effect. The plasticizer contributes to the flexibility and elongation of the tablet 
matrix therefore help to maintain the integrity of the tablet. As shown in Figure 4-6, the 
tablets prepared with co-processed excipient F1 (ATEC as plasticizer) showed similar 
dissolution profile as the tablets prepared with co-processed excipient F2 (ATBC as 
plasticizer). The similarity factor f2 value of these two dissolution profile is 77.78. This 
indicates the type of the plasticizer in co-processed excipient has less impact on drug 
release from this matrix system. 
 
 
4.3.7 The effect of pH of dissolution medium on drug dissolution 
 
The model drug propranolol hydrochloride is a hydrochloride salt with pka 9.5. 
When the pH ranges from1.2 to 7.4, it shows a pH independent solubility profile. The 
hydrophilic polymer Polyox® 303 is a nonionic polymer and its solubility is not sensitive 
to pH.  The result of pH effect on drug dissolution was shown in Figure 4-7. The drug 
release profiles of H2 in three different media are very close to each other.  Select water 
release as reference, the f2 value of the simulated gastric fluid (SGF) is 67.68 and the 
simulated intestinal fluid (SIF) is 76.99. The result suggests this novel matrix system 
provides a pH independent dissolution profile for a pH insensitive drug. But for a pH 
sensitive drug, the dissolution profile may change based on the solubility of drug in 
different pH medium. 
 
 
4.3.8 Drug release mechanism study 
 
 
4.3.8.1 Optical microscopic observation 
 
Figures 4-8 and 4-9 recorded the water penetration and components changes of 
two colored tablet formulations of H0 and H2 during 12 hours dissolution. Formulation 
H0 does not contain any hydrophilic polymer. The white drug powder was uniformly 
distributed in the matrix before dissolution as described in Figure 4-8A and B. Upon 
contacting with water, the surface drug dissolved in the water and left the pores on the 
surface of the tablet (Figure 4-8B) and the pore size is as same as the size of undissolved 
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Figure 4-6. The effect of co-processed excipients on drug dissolution  
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A: Tablet surface at 0 hour; B:  Tablet cross section at 0 hour; C: tablet surface at 1 hour; 
D: tablet cross section at 1 hour; E: Tablet surface at 6 hours; F: tablet cross section at 6 
hours; G: tablet surface at 12 hours; F: tablet cross section at 12 hours.  
Figure 4-8. Microscopic picture of colored tablets (H0) during dissolution 
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A: Tablet surface at 0 hour; B: tablet cross section at 0 hour; C: tablet surface at 1 hour; 
D: tablet cross section at 1 hour; E: tablet surface at 6 hours; F: tablet cross section at 6 
hours; G: tablet surface at 12 hours; F: tablet cross section at 12 hours. 
  
Figure 4-9. Microscopic picture of colored tablets (H2) during dissolution 
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drug. Figure 4-8D, E and F demonstrated the slow water penetration process through the 
pores into the core of the tablet. As shown in Figure 4-8H, even water completely wet 
the tablet at 12 hours, there are still around 40% drug remaining in the center of the tablet 
and could not diffuse through the tightly matrix structure. As described in Table 4-7, the 
geometric dimension of H0 kept constant during 12 hours dissolution. The slower water 
penetration rate and the compacted tablet structure result incomplete release. 
 
Formulation H2 contains 5% Polyox 303 and the color of Polyox 303 is orange in 
the Figure 4-8. Initially, the hydrophilic polymer, drug and the co-processed excipient 
were uniformly distributed in the matrix (Figure 4-9A and B). After 1h, the hydrophilic 
polymer located on the surface was swollen and formed a viscous gel. The large pores 
filled with viscous gel on the tablet surface were observed (Figure 4-9C). This gel can 
prevent the rapid surface drug release initially. With the swelling of the hydrophilic 
polymer, the tablet dimensions changed both radically and axially at 1 hour (Figure 4-9D 
and Table 4-7). At 6 hours, the hydrophilic polymer located on the surface dissolved and 
left the swollen pores on the surface for water penetration. The tablets continued to 
expand and the water almost wetted the whole tablet at 6 hours.  Due to the present of 
large pores, water penetration rate for formulationH2 is much faster than formulation H0. 
The geometric dimension of the tablet at 12 hours was similar to 6 hours as shown in 
Table 4-7. This indicates the hydrophilic polymer was completely hydrated at 6 hours. 
After 6 hours, the polymer erosion is the major activity of the hydrophilic polymer within 
the tablet matrix. At 12 hours, highly porous structure of the tablet can be observed in 
Figure 4-9G and 9H.  Because the large pores generated while the dissolution, water can 
easily penetrate through these large pores and extract drug from the matrix. Therefore 
completely drug release can be expected from formulation H2.  
 
 
4.3.8.2 Mathematic model fit 
 
The dissolution profiles of three formulations containing different pore formers 
were fitted to logarithm transformed power law equation and Peppas and Shalin equation. 
The results were shown in Figures 4-10 and 4-11. All the three dissolution profiles 
displayed a good fit to both the power law equation and Peppas and Shalin equation 
(R2>0.98). The drug release mechanism can be determined by the n value which is the 
slope of logarithm transformed power law equation and R/F ratio which can be calculated 
from the Peppas and Shalin equation. The n value for P1 (lactose as pore former) is 
slightly higher than 0.45, this suggest the major drug release is controlled by Fickian 
diffusion. This is confirmed by the Peppas and Shalin equation. The k2 value for P1 in 
Peppas and Shalin equation is negative. The negative value of k2 means the structure 
relaxation can be neglected. The n value P2 formulation (Starch 1500 as pore former) in 
power law equation is 0.5703. This value is higher than 0.45 and indicates both Fickian 
diffusion and polymer relaxation play a role in controlling the drug release. The k2/k1 
ratio is 0.206 and the R/F ratio for P2 formulation is always less than 1 within 12 hours 
dissolution time. This indicates the Fickian diffusion is dominant mechanism for P2 
tablets. For the H2 formulation (Polyox 303 as pore former), the n value is 0.6781. It is 
also an anomalous transport mechanism. Both diffusion and polymer swelling take place. 
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Table 4-7. Tablets size change during dissolution 
 
 
 
  
Time 
H0 H2 
Thickness 
(mm) 
Diameter 
(mm) 
Thickness 
(mm) 
Diameter 
(mm) 
0 hour 3.68 9.55 3.70 9.55 
1 hour 3.70 9.60 4.55 9.81 
6 hours 3.70 9.60 6.07 9.85 
12 hours 3.70 9.60 6.11 9.84 
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The k2/k1 ratio for H2 is 0.892. When t <1.3 hours, R/F is less than 1. The Fickian 
diffusion is the dominant release mechanism. This is diffusion is caused by the release of 
the surface drug. When t>1.3 hours, the matrix relaxation is the dominant release 
mechanism. This is caused by the polymer swelling and erosion. 
 
 
4.4 Conclusions 
 
A novel swellable porous matrix tablet was successfully developed by 
incorporation of small amounts of hydrophilic polymer into the plastic inert matrix. The 
drug release from this novel matrix formulation showed a limited burst release initially 
with complete release at final stage. 
 
The drug release rate from this matrix system is independent with the type and the 
particle size of hydrophilic polymer and the pH of dissolution medium. The drug release 
rate increased when the hydrophilic polymer concentration less than 5%. Further increase 
the hydrophilic polymer concentration to 10% did not further increase the drug release 
rate. The low viscosity grade hydrophilic polymer result rapid burst release and 
incomplete final release, while middle to high viscosity grades of hydrophilic polymer 
avoided these problems. The optical microscopy results revealed the initial gel formation 
on the tablet surface with development of a swollen porous structure in the matrix 
network during dissolution. The drug release is controlled by both drug diffusion and 
polymer relaxation. The Fickian diffusion is the dominant release mechanism at initial 
stage and the polymer relaxation becomes dominant thereafter. 
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Chapter 5. Application of the Novel Matrix System on the Drugs with Different 
Solubility 
 
 
5.1 Introduction 
 
The final objective of this work is to apply the plasticized cellulose acetate 
excipient and the hydrophilic polymer involved novel matrix system to the sustained 
release matrix tablets. In order to test the suitability of this swollen porous matrix system, 
we selected three different drugs with different solubility as model drugs. A β-adrenergic 
blocking agent propranolol hydrochloride with water solubility more than 150 mg/ml at 
37°C was selected as the freely water soluble model drug [83].  Theophylline which used 
for treatment of chronic asthma with water solubility of 9.9 mg/ml at 37°C was selected 
as sparingly water soluble model drug [36].  The short acting sulphonyl urea drug 
glipizide with solubility of 0.078 mg/ml in pH 6.8 and insoluble in water and acidic pH 
was selected as poorly water soluble model drug [23, 84].  Propranolol hydrochloride and 
glipizide all have a short elimination half-life and theophylline has a fairly narrow 
therapeutic plasma concentration.  The clinical effect of those drugs can be improved by 
using sustained release formulations. The feasibility of the co-processed excipient and the 
novel matrix system in these three drugs are evaluated by comparison of dissolution 
profiles with USP specifications or commercial product. 
 
 
5.2 Materials and Methods 
 
 
5.2.1 Materials 
 
Cellulose acetate with 39.8% acetyl content and 38 cp viscosity (CA 398-10 NF, 
Eastman, Kingsport, TN) was used as the main polymer in this study. Triethyl citrate 
(TEC), acetyltriethyl citrate (ATEC), acetyltributyl citrate (ATBC) and dibutyl sebacate 
(DBS) (Morflex Inc., Greensboro, NC) were used as plasticizers. Milled dicalcium 
phosphate dihydrate (milled DCP Innophos Inc., Cranbury, IL) were used as filler. 
Magnesium stearate (Mallinckrodt, Paris, KY) was used as a lubricant.  Propranolol 
hydrochloride was used as water soluble model drug, Theophylline anhydrous (BASF, 
Ludwigshafen, Germany) was used as sparing water soluble drug and glipizide was used 
as poorly water soluble drug. Three different viscosity grades of HPC(Klucel® 
EXF,GXF and HXF, Ashland, Wilmington, DE), high viscosity grade of polyethylene 
oxide (Polyox® 303, Dow Chemical, Midland MI) and high viscosity grade of sodium 
alginate (KELTONE® HVCR, FMC biopolymer, Philadelphia, PA) were selected as 
hydrophilic polymers. Glucotrol XL® 10 mg (Pfizer, Peapack, NJ) was used as a 
commercial product for dissolution profile comparison. 
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5.2.2 Methods 
 
 
5.2.2.1 Tablets preparation 
 
 
5.2.2.1.1 Propranolol hydrochloride tablets 
 
The tablet formulations were listed in Tables 5-1 and 5-2. The drug was mixed 
with intragranular hydrophilic polymer by passing through 20 mesh sieve three times.	
The mixture was compacted to form a ribbon on the TFC-LAB Micro Roller Compactor 
(Vector, Marion, IA). The settings for the roller compactor are: Roller speed: 2rpm, 
screw speed: 20rpm, roller pressure: 5 MPa. The ribbons were milled by the mini-
oscillator mounted with an 18 mesh sieve.  The dry granules were mixed with other 
ingredients by passing through 16 mesh sieve for three times and then compressed on a 
Carver Press (Carver Inc., Wabash, IN)  by 3/8 inch flat face punch at 1.5 metric ton 
compression force with 3 second dwell time. The target weight was 400mg. 
 
 
5.2.2.1.2 Theophylline anhydrous tablets  
 
The tablet formulations were listed in Table 5-3. The tablets were prepared by a 
direct compression method. All the ingredients were mixed by passing through 20 mesh 
sieve for 3 times. The mixture was compressed on a Carver Press (Carver Inc., Wabash, 
IN) by 3/8 inch flat face punch at 1.5 metric ton compression force with 3 second dwell 
time. The target weight was 400mg. 
 
 
5.2.2.1.3 Glipizide tablets 
 
The tablet formulations were listed in Tables 5-4 and 5-5. The tablets were 
prepared by a direct compression method. All the ingredients were mixed by passing 
through 20 mesh sieve for 3 times. The mixture was compressed on a Carver Press 
(Carver Inc., Wabash, IN) by 1/4 inch flat face punch at 1.0 metric ton compression force 
with 3 second dwell time. The target weight was 200 mg. 
 
 
5.2.2.2 In vitro dissolution study 
 
 
5.2.2.2.1 Propranolol hydrochloride and theophylline 
 
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation, 
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch 
were tested. 900 ml of distilled water and pH 7.4 phosphate buffer at 37 ± 0.5°C was used 
as the dissolution medium to evaluate the release of propranolol hydrochloride and  
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Table 5-1. Formulations for propranolol hydrochloride tablets prepared with 
different intragranular hydrophilic polymers 
 
Ingredients  Percentage (%) PR1 PR2 PR3 
Propranolol hydrochloride 20 20 20 
Polyox® 303(intragranular) 5 0 0 
HPC HXF (intragranular) 0 5 0 
HPC GXF (intragranular) 0 0 5 
Spray dried excipient F2 74.5 74.5 74.5 
Magnesium Stearate 0.5 0.5 0.5 
Total  100 100 100 
 
 
 
 
Table 5-2. Formulations for propranolol hydrochloride tablets prepared with 
intragranular and extragranular hydrophilic polymers 
 
 
 
  
Ingredients Percentage (%) 
PR4 PR5 
Propranolol hydrochloride 20 20 
HPC GXF(intragranular) 5 0 
HPC EXF (intragranular) 0 5 
Polyox® 303(extragranular) 5 5 
Spray dried excipient F2 69.5 69.5 
Magnesium Stearate 0.5 0.5 
Total  100 100 
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Table 5-3. Formulations of theophylline tablets prepared with different 
concentrations of hydrophilic polymers 
 
 
 
 
 
Table 5-4. Formulations of glipizide tablets with different concentrations of co-
processed excipients 
 
 
 
 
 
Table 5-5. Formulations of glipizide tablets prepared with different 
concentrations of sodium alginate 
 
 
  
Ingredients  Percentage (%) T1 T2 T3 
Propranolol hydrochloride 25 25 25 
Spray dried excipient F2 74.5 69.5 64.5 
Polyox® 303 0 5 10 
Magnesium Stearate 0.5 0.5 0.5 
Total  100 100 100 
Ingredients  Percentage (%) G1 G2 G3 G4 
Glipizide 5 5 5 5 
Spray dried excipient F2 5 7.5 10 20 
Lactose 316 89.5 87.0 84.5 74.5 
Magnesium Stearate 0.5 0.5 0.5 0.5 
Total  100 100 100 100 
Ingredients  Percentage (%) G5 G6 G7 
Propranolol hydrochloride 5 5 5 
Spray dried excipient F2 20 20 20 
Lactose 316 73.5% 72.5% 71.5% 
Sodium Alginate HVCR 1 2 3 
Magnesium Stearate 0.5 0.5 0.5 
Total  100 100 100 
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theophylline respectively. The paddle speed was 50rpm. The samples were taken at 
predetermined time points for 12 hours. The absorbance of the solution was measured at 
289 nm for propranolol hydrochloride and 274 nm for theophylline by a UV-
spectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug concentration 
and the percentage of drug release were calculated by the software DissLab®. 
 
 
5.2.2.2.2 Glipizide 
 
The USP Apparatus II (Hanson SR-8 Plus, Hanson Research Corporation, 
Chatsworth, CA) was used to evaluate the drug release. Three tablets from each batch 
were tested. Hydrochloric acid (0.1 N, 750 ml) was used as the dissolution media for the 
first 2 hours. Then, pH was adjusted to 6.8 by adding 250 ml of 1N tribasic phosphate. 
The paddle speed is 50 rpm. The samples were taken at predetermined time points for 14 
hours. The absorbance of the solution was measured at 287 nm by a UV-
spectrophotometer (Perkin-Elmer Corporation, Norwalk, CT). The drug concentration 
and the percentage of drug release were calculated by the software DissLab®. 
 
 
5.2.2.2.3 Similarity factor f2 
 
The difference of drug dissolution profiles was evaluated by using f2 value as 
described in Equation 5-1. 
 
 f2=50×log{[1+(1+1/n)∑ (Rtt=1 -Tt)
2
]
-0.5
×100} (Eq. 5-1) 
 
where f2 is a similarity factor, n is the number of sample times, Rt is the average 
percentage of drug released at time t for the reference sample, Tt is the average 
percentage of drug released at time t for the test sample. According to FDA’s guidance 
for industry, if f2 values were greater than 50, the two dissolution profiles can be consider 
as similar or equivalent. 
 
 
5.2.2.3 Mathematic model fitting 
 
 
5.2.2.3.1 Power law equation 
 
Drug-release mechanism was first studied by fitting the dissolution data to the 
power law equation [45]. 
 
 Mt/ M∞=k*tn (Eq. 5-2) 
 
where Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of 
drug released at infinite time; k is release constant incorporating structural and geometric 
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characteristics of the system, and n is the release exponent indicating the mechanism of 
drug release.  
 
The release exponent ‘n’ in the power law takes multiple values based on 
geometry of the system. For a cylinder shape tablets, if n<0.45, the major release 
mechanism is Fickian  diffusion; if the n value >0.89, Case-II transport in which the 
polymer relaxation is the rate limiting process; if n value between 0.45 and 0.89,  the 
“anomalous transport” takes place where  both  of drug diffusion and swelling of the 
polymer are involved. 
 
 
5.2.2.3.2 Peppas and Shalin equation 
 
Peppas and Shalin equation is a modification of power law equation [50]. It was 
performed by decoupling diffusion and “Case-II transport” with the following expression: 
 
 Mt/ M∞=k1*tm + k2*t2m (Eq. 5-3) 
 
where k1 and k2 are the release constants and m is the pure Fickian diffusion exponent.  
The exponent m is related to the aspect ratio of the tablets. For the aspect ratio of tablet 
around 3, the m value is 0.45. And m=0.45 was used in our study. First term in the right 
hand of the Equation 5-3 represents the contribution of Fickian diffusion (F) and the 
second term represents the contribution of tablet structure relaxation (R). R/F ratio can be 
calculated using Equation 5-4: 
 
 R/F = k2*tm/k1 (Eq. 5-4) 
 
The dominant drug release mechanism can be determined by the R/F ratio at any 
given time during dissolution. The model fit was performed by the software GraphPad 
Prism 4. 
 
 
5.3 Results and Discussion 
 
 
5.3.1 Propranolol hydrochloride matrix tablets 
 
According to the dissolution results in Chapter 4, incorporation of the hydrophilic 
polymer to the matrix significantly increase the drug release at final stage, but the initial 
burst release still exists. In order to minimize the burst effect for a freely water soluble 
drug, the roller compaction method was used in this chapter. 
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5.3.1.1 The effect of roller compaction process on drug release 
 
The Figure 5-1 displayed the effect of roller compaction of drug with hydrophilic 
polymers on drug release. Since the dissolution profiles of the direct compression 
formulations containing 5% Polyox® 303, HPC HXF and HPC GXF were very close 
(data was not shown). We only selected the direct compression formulation H2 (5% 
Polyox® 303) for comparison.  The results shown in Figure 5-1 demonstrated the drug 
release rate was affected by the roller compaction process as well as the polymer used in 
this process. Roller compaction of the drug with the hydrophilic polymer can decrease the 
drug release rate in this matrix system. This impact was more obvious at the final stage 
than the initial stage. The hydrophobicity and the viscosity of the hydrophilic polymer 
also play a role in drug release rate. The tablets prepared by more hydrophobic polymer 
HPC and the middle viscosity grades of HPC showed a slower release rate  than the more 
hydrophilic polymer Polyox® 303 and the high viscosity grade HPC. Table 5-6 listed the 
initial drug release (1 hour) and the final drug release (12 hours) for these four 
formulations. The results showed not only a decrease in drug release in initial release for 
all roller compacted formulations, but also a significant decrease at the final stage. The 
decrease of the initial release might be due to the freely water soluble drug embedded in 
the hydrophilic polymer. The viscous gel directly surrounding the drug particles can help 
to reduce the rapid initial drug release. The hydrophilic polymer with more 
hydrophobicity and less viscosity has less water absorption initially, therefore less drug 
diffusion through the gel and an improved initial retarding effect was observed.  The 
decrease of the final drug release might due to reduction in the swellability of the 
hydrophilic polymer during the roller compaction. Loss of the swellability of the 
hydrophilic polymer will result in a less porous structure of the final tablets. Therefore 
incomplete drug release is seen in the dissolution time studied. 
 
 
5.3.1.2 The effect of the intragranular polymer on drug release 
 
When a controlled release formulation is developed, typically less burst effect and 
complete release are required. Roller compaction of the drug with the hydrophilic 
polymer not only limited the burst release, but also suppressed the final release. In order 
to reach complete release, five percent of Polyox® 303 was added extra granularly. The 
purpose of the extragranular Polyox® 303 is to expand the tablet and generate the highly 
porous tablet structure. Figure 5-2 displayed the effect of extragranular hydrophilic 
polymer on the drug release. The percentages of initial and final drug release for these 
four formulations were tabulated in Table  5-7. The extragranular Polyox® 303 only 
increased the final drug release for roller compacted formulations and did not interfere 
with the initial release. The formulation PR5 prepared with 5% intragranular low 
viscosity grade HPC EXF and 5% extragranular Polyox® 303 showed slowest initial 
release and complete final release. As shown in Table 5-8, the release profile of PR5 
meets the USP requirements for propranolol hydrochloride sustained release formulation.  
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Figure 5-1. Effect of roller compaction on propranolol hydrochloride release 
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Table 5-6. The drug release results of formulations containing intragranular 
hydrophilic polymers at 1 hour and 12 hours 
 
* Statistically significant difference with H2 formulation. (P< 0.05) 
 
 
 
  
Formulations 1 hour  12 hours 
H2 (5% Polyox® 303) 19.36±0.56 90.69±0.52 
PR1 (5% intragranular Polyox® 303) 18.18±0.39 79.09±2.77* 
PR2 (5% intragranular HPC HXF) 16.10±0.61* 76.81±1.81* 
PR3 (5% intragranular HPC GXF) 14.40±0.45* 59.80±2.18* 
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Table 5-7.  The drug release results of formulations containing intragranular and 
extragranular hydrophilic polymers at 1 hour and 12 hours 
 
* Statistically significant difference with H2 formulation. (P< 0.05) 
 
 
 
 
Table 5-8. Comparison of propranolol hydrochloride tablets prepared from PR1 
and USP specifications 
 
 
 
 
 
  
Formulations 1 hour 12 hours 
H2 (5% Polyox 303) 19.36±0.56 90.69±0.52 
PR3 (5% intragranular HPC GXF) 14.40±0.45* 59.80±2.18* 
PR4 (5% intragranular HPC GXF+5% 
extra granular Polyox® 303) 14.54±0.19
* 82.88±1.78* 
PR5 (5% intragranular HPC EXF+5% 
extra granular Polyox® 303) 11.20±0.51
* 88.23±1.38 
Time Requirements PR5 
1h <20% 11.20 ±0.51 
3h 20-45% 31.97±0.66 
6h 45%-60% 49.90±0.39 
12h >80% 88.23±1.38 
 116 
5.3.1.3 Mathematic model fit 
 
The dissolution profiles of formulation H2 (5% Polyox 303), PR1 (5% 
intragranular Polyox® 303) and PR5 (5% intragranular HPC EXF+5% extra granular 
Polyox 303) were fitted to logarithm transformed power law equation. The results were 
displayed in Figure 5-3. Three dissolution profiles all exhibit good fit for power law 
equation (R2>0.99). The n values for formulation H2 and PR1 falls in the range of 0.45-
0.89 which indicates both Fickian diffusion and matrix relaxation are responsible for 
controlling the drug release. Loss of swellability of hydrophilic polymer in roller 
compaction results less polymer relaxation, therefore smallest n value for formulation 
PR1 was observed. The n value for formulation PR5 is above 0.89 which indicates the 
dominant drug release mechanism is matrix relaxation. This result was confirmed by 
Peppas and Shalin equation (Figure 5-4). The k1 value for formulation PR5 is negative 
which means the Fickian diffusion can be neglected. This results suggests roller 
compaction of the freely water soluble drug with the low viscosity hydrophilic polymer 
can suppress the initial rapid drug diffusion and change the drug release mechanism from 
Fickian diffusion to matrix relaxation.  
 
 
5.3.2 Theophylline anhydrous tablets 
 
 
5.3.2.1 Formulation development 
 
Theophylline is a week acid with pka 8.8 [85]. The solubility of theophylline 
remains constant when the pH ranges from1 to 6.8. The solubility increases as the 
environmental pH climbing to 7.0 and above. This is BCS I drug with high solubility and 
high permeability. According to USP test method, pH 7.4 phosphate buffer is used as the 
dissolution medium for theophylline sustained release tablets. The formulation 
development of theophylline sustained release tablets in our study was carried by 
incorporating different concentration of hydrophilic polymer to the plastic inert matrix 
system. Three formulations were tried and the dissolution profiles were displayed in 
Figure 5-5. The formulation T1 prepared with only plasticized co-processed excipient 
showed a significant burst release and the incomplete final release. When we 
incorporated  hydrophilic polymer Polyox 303 to the above system, unlike rapid gel 
diffusion rate of  freely water soluble drug propranolol hydrochloride initially, the 
sparingly water soluble drug theophylline has a limited diffusion through the viscous gel. 
Therefore the initial release was suppressed by incorporating the hydrophilic polymer. 
When the concentration of the hydrophilic polymer increased from 5 to 10%, the initial 
release was further decreased. The significant increase of the final release (p<0.05) were 
observed for both 5% and 10% Polyox 303 formulations. The solubility of theophylline is 
only one tenth of propranolol hydrochloride and could not generate enough osmotic 
pressure inside the tablet. A larger amount of hydrophilic polymer was required in order 
to have a complete final release. The dissolution profile of formulation T3 showed a good 
satisfaction with the USP requirements as shown in Table 5-9. 
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Figure 5-3. Power law equation fit of propranolol hydrochloride release profile 
 118 
 
 
 
 
  
0 1 2 3 4 5 6 7 8 9
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
H2 (5% Polyox 303)
PR1 (5% intragranular Polyox 303)
PR5 (5%  intragranular HPC EXF + 5% extragranular
Polyox 303)
H2: Y=10.14*t0.45+9.045*t0.9
 R2=0.9980
PR1: Y=12.63*t0.45+5.855*t0.9
 R2=0.9963
PR2: Y=1.497*t0.45+11.35*t0.9
 R2=0.9966
Time (hrs)
Pe
rc
en
ta
ge
 o
f d
ru
g 
re
le
as
ed
 %
Figure 5-4. Peppas and Shalin equation fit of propranolol hydrochloride release 
profile 
 119 
 
 
 
  
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12
T3 (10%Polyox 303)
T2 (5%Polyox 303)
T1 (Without pore 
former)
Pe
rc
en
ta
ge
of
 d
ru
g 
re
le
as
ed
 (%
)
Time (hrs)
Figure 5-5. Effect of hydrophilic polymer concentrations on theophylline release 
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Table 5-9. Comparison of theophylline tablets prepared from T3 and USP 
specifications  
 
 
 
 
 
 
 
 
Time USP requirements T3 
1h 3-15% 8.64±0.94 
2h 12-30% 16.63±1.22 
4h 25-50% 31.06±1.49 
5h 30-60% 38.59±1.59 
8h 55-75% 58.59±1.77 
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5.3.2.2 Mathematic model fit  
 
The dissolution profiles of three theophylline formulations were fitted to 
logarithm transformed power law equation as shown in Figure 5-6. Formulation T1 
(without hydrophilic polymer) showed a typical diffusion controlled drug release with n 
value less than 0.45. Formulation T2 (5% Polyox 303) and T3 (10 Polyox 303) all 
showed the diffusion and structure relaxation combined release mechanism with n value 
between 0.45-0.89. The dominant drug release mechanism of T2 and T3 can be 
determined by the results of Peppas and Shalin equation fit (Figure 5-7). The k2/k1 ratio 
for T2 is 1.1 which indicates the diffusion is the major mechanism initially and the 
polymer relaxation is dominant afterwards. The k1 value for T3 formulation is negative 
which indicate the diffusion mechanism is minimal in controlling the drug release. The 
drug release difference between T2 and T3 can be explained by the difference of gel 
strength initially. The higher gel strength was obtained by the formulation T3 which 
containing more hydrophilic polymer. The higher gel strength effectively prevent the 
initial burst release for a sparingly water soluble drug theophylline. 
 
 
5.3.3 Glipizide tablets 
  
Glipizide is a weak acid with pka 5.9. It is insoluble in the pure water and shows a 
pH dependent solubility. The solubility of glipizide is 0.078mg/ml in pH 6.8 buffer and 
practical insoluble in acidic pH.  As suggest in USP, the dissolution test of glipizide 
sustained release formulations was performed in 0.1 N hydrochloric acid solution for 2 
hours, then pH 6.8 buffer for another 12 hours in our study. The commercialized glipizide 
sustained release formulation is an osmotic pump tablet named Gluctrol XL®. It is 
bilayer tablet and coated by a semi-permeable membrane with a laser drilled hole on the 
surface [23]. The drug release can be precisely controlled from this device, but the 
manufactures of osmotic pump devices is complicated and expensive involving many 
process variables. In this chapter, we are trying to develop a direct compressed matrix 
tablet to control the release of glipizide by using the plasticized co-processed excipient. 
 
 
5.3.3.1 The effect of co-processed excipient on drug release  
 
For development of sustained release inert matrix tablet for a water insoluble 
drug, a pore former is essential to achieve the complete release. The traditional pore 
former lactose monohydrate was tried first. In order to obtain complete release for 
glipizide, a large amount of lactose in the formulation was required and the amount of co-
processed excipient is relatively small. For the purpose of convenience, we used the 
concentration of co-processed excipient to represent each of the formulation.  The 
dissolution profiles of the reference tablet Gluctrol XL® and tablets prepared with 
different concentrations of co-processed excipients were displayed in Figure 5-8.  
Because glipizide is insoluble in acidic pH, all the tablets in Figure 5-8 showed a delayed 
release profile of two hours. Gluctrol XL® exhibits nearly zero order release between 2-
14 hours. Except the formulation G4 which contains 20% co-processed excipient, all 
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other formulations prepared with the co-processed excipient and lactose in Figure 5-8 
were disintegrated during dissolution. Because the hydrophobic nature of the glipizide 
and certain shape and network structure of each disintegrated subunit were maintained 
during the dissolution, the sustained drug release profile still can be achieved for these 
formulations. Disintegration of the tablet significantly increases the surface area exposed 
in dissolution medium and reduces the diffusion pathway of the drug, therefore helping to 
reach complete final release.  But the particle size of each disintegrated subunit is not 
identical for different tablets prepared with same formulation which causes a large 
variation in the dissolution within the batches as shown in Figure 5-8. Considering the f2 
values for each formulation, only formulation G3 prepared with 7.5% co-processed 
excipient is greater than 50. (f2=52.08) This indicates the dissolution profile of G3 is 
similar to the reference product Gluctrol XL® and can be further evaluated by an in vivo 
bioequivalence study. 
 
 
5.3.3.2 The effect of hydrophilic polymer on drug release 
 
The formulation development of glipizide sustained release matrix tablet was also 
performed by incorporating different concentrations of the hydrophilic polymer in the 
matrix system. Since the glipizide is a poorly soluble drug and requires more channels for 
diffusion, the proper amount of lactose combined with 20% co-processed excipient were 
used to construct the matrix system. In order to mimic the 2 hours delayed release as the 
reference tablet, a pH sensitive polymer sodium alginate was selected.  Sodium alginate 
is insoluble and cannot swell in acidic pH but it will hydrate and swell in neutral and 
basic pH. Incorporating sodium alginate in the matrix tablet can help to keep tablet 
structure in acid pH and generate enough porous for drug diffusion in neutral and basic 
pH. The effect of the concentrations of hydrophilic polymer on drug release was shown 
in Figure 5-9. All the tablets in Figure 5-9 remained intact during 14 hours dissolution. 
The drug release rate increasing as the concentration of sodium alginate increased. Since 
the tablets did not disintegrate during dissolution, less batch variation (SD<4%) of 
dissolution was observed.  The f2 value for formulation G6 containing 2% sodium 
alginate and 20% co-processed excipient is greater than 50 (f2=65.03).  This suggests 
formulation G6 has the similar dissolution profile with reference tablet Gluctrol XL®. 
 
 
5.3.3.3 Mathematic model fit 
 
The logarithm transformed power law equation was used to fit the dissolution 
profiles of formulation G2 and G5 (Figure 5-10). Since all the formulations exhibit two 
hours delay, the mathematic model fit all took 2 hours as starting point. The formulation 
G2 (7.5% co-processed excipient) showed a combined diffusion and structural relaxation 
controlled drug release mechanism with n value between 0.45 and 0.89. The dominant 
drug release mechanism of G2 can be derived from Peppas and Shalin equation fit 
(Figure 5-11). The k2/k1 ratio for G2 is 1.03 and the R/F ratio can be calculated from 
Equation 5-4. The result indicates the diffusion is the dominant mechanism within the 
first hour and the structure relaxation is dominant afterwards. Because the disintegrating 
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of G2 tablets took place in the first hour, the surface drug diffusion is the major release 
mechanism. After the tablet completely disintegrated, the disintegrated particles were in 
charge of controlling the drug release and the release mechanism was switched to 
structure relaxation after 1 hour. Formulation G6 (20% co-processed excipient +2.0% 
sodium alginate) showed structural relaxation controller drug release with n value greater 
than 0.89. The k1 value of formulation G6 in Peppas and Shalin equation is negative 
which confirmed the dominant drug release mechanism is structural relaxation. 
 
 
5.4 Conclusions  
 
The sustained release matrix tablets for three different drugs with different 
solubility were successfully developed by using the novel swollen porous matrix system. 
The optimized formulations for these three drugs either meet the USP specifications or 
have similar dissolution profile as the commercial product. For a freely water soluble 
drug propranolol hydrochloride, a novel roller compaction method was successfully 
applied to reduce the initial burst release. The tablets prepared by the roller compacted 
granules showed suppressed burst release and complete final release. The power law 
equation and Peppas and Shalin revealed the drug release was controlled by the structure 
relaxation. For sparingly water soluble drug theophylline, incorporating the hydrophilic 
polymer can successfully reduce the burst release as well as improve the final release. 
When 10% percent of hydrophilic polymer presents in the formulation, the initial burst 
was further reduced and the drug release mechanism is switched from initial diffusion 
controlled to completely structure relaxation controlled.  Two successful sustained 
release formulations of poorly water soluble drug glipizide were obtained by using the 
plasticized co-processed excipient. Both of them have similar dissolution profile as the 
commercial product Gluctrol XL®. But the formulation prepared with lactose as pore 
former showed a big variation in dissolution profile while another formulation prepared 
with both lactose and hydrophilic polymer as pore former exhibited less variation in 
dissolution profile and higher f2 value.  
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